Antiinflammation Derived Suzuki-Coupled Fenbufens as COX-2 Inhibitors: Minilibrary Construction and Bioassay

Shiou-Shiow Farn 1,2,†, Yen-Buo Lai 1,†, Kuo-Fong Hua 3,†, Hsiang-Ping Chen 1, Tzu-Yi Yu 1, Sheng-Nan Lo 2, Li-Hsin Shen 1, Rong-Jiun Sheu 4 and Chung-Shan Yu 1,4,*

1 Department of Biomedical Engineering and Environmental Sciences, National Tsinghua University, Hsinchu 30013, Taiwan; amanda@iner.gov.tw (S.-S.F.); s109012467@m109.nthu.edu.tw (H.-P.C.); s109012079@m109.nthu.edu.tw (T.-Y.Y.); lisinshen.nthu@gmail.com (L.-H.S.)
2 Isotope Application Division, Institute of Nuclear Energy Research, Taoyuan 32546, Taiwan; loshengnan@iner.gov.tw
3 Department of Biotechnology and Animal Science, National Ilan University, Ilan 26007, Taiwan; kuofenghua@gmail.com
4 Institute of Nuclear Engineering and Science, National Tsinghua University, Hsinchu 30013, Taiwan; rjsheu@mx.nthu.edu.tw
* Correspondence: csyu@mx.nthu.edu.tw
† These authors contributed equally to this work.

Abstract: A small fenbufen library comprising 18 compounds was prepared via Suzuki Miyara coupling. The five-step preparations deliver 9–17% biphenyl compounds in total yield. These fenbufen analogs exert insignificant activity against the IL-1 release as well as inhibiting cyclooxygenase 2 considerably. Both the para-amino and para-hydroxy mono substituents display the most substantial COX-2 inhibition, particularly the latter one showing a comparable activity as celecoxib. The most COX-2 selective and bioactive disubstituted compound encompasses one electron-withdrawing methyl and one electron-donating fluoro groups in one arene. COX-2 is selective but not COX-2 to bioactive compounds that contain both two electron-withdrawing groups; disubstituted analogs with both resonance-formable electron-donating dihydroxy groups display high COX-2 activity but inferior COX-2 selectivity. In silico simulation and modeling for three COX-2 active—p-fluoro, p-hydroxy and p-amino—fenbufens show a preferable docking to COX-2 than COX-1. The most stabilization by the p-hydroxy fenbufen with COX-2 predicted by theoretical simulation is consistent with its prominent COX-2 inhibition resulting from experiments.

Keywords: COX-2 selectivity; synergistic; COVID-19; biaryl; inflammasome

1. Introduction

Nonsteroidal anti-inflammatory drugs (NSAIDs) are characterized as cyclooxygenase (COX) inhibitors. NSAIDs have recently received significant attention, predominantly due to its unidentified adverse effects on treatments of the COVID-19 pandemic. In the course of COVID-19 therapy, one of the NSAIDs, Ibuprofen, induces the overexpression of angiotensin converting enzyme (ACE-2) receptor which may enable the entrance of SARS coronaviruses into the host cells [1]. Thus, the World Health Organization discouraged the repurposing of COX inhibitor.

The rising concerns of the adverse effects have been challenged by the report by Ong et al. [2]. They performed a large randomized controlled trial for the infected patients to assess COX inhibitor NSAIDs and COXIBs as appropriate therapeutics or adjuvant drugs against COVID-19. The supporting drugs administered with the NSAID ‘Etoricoxib’ reduced the levels of Interleukin-6, thus requiring no noninvasive or invasive ventilation or transfer to the intensive care units. Interestingly, the supporting drugs administered with NSAIDs did not develop adverse effects typically found in the cyclooxygenase inhibition...
therapy, e.g., gastrointestinal or cardiovascular intricacies. NSAIDs, such as aspirin, indomethacin, diclofenac, and celecoxib, have provided a silver lining in adjuvant COVID-19 therapy [3]. This can be attributed to their roles in confusing SARS viral replication and the deactivation of inflammasome. Synergistic inhibition of H5N1 viral infection with representative antiviral drugs is also remarkable.

Inflammation can be mediated through various pathways. Among them, COX plays a pivotal role. COX enzymes are principally classified into three types, i.e., COX-1, COX-2 and COX-3. COX-1 is constantly expressed in most tissues and functions as a house-keeping enzyme whereas COX-2 enzyme is induced in stress conditions and overexpressed in inflammation sites [4,5]. The uncommon COX-3 is a COX-1 splice variant [6–8]. In the presence of COX, arachidonic acid (AA) was metabolized to form prostaglandins (PG) via two sequential steps: a preliminary oxidation to PGG2 by using a COX followed by reduction to a labile endoperoxide intermediate PGH2 by peroxidase (POX). COXs have been treated with inhibitor NSAIDs but the mechanism remains complicated because AA and the inhibitor interact with COX reciprocally. COX-1 and COX-2 are also less frequently named as prostaglandin endoperoxide synthase-1 and -2 (PGHS-1 and -2) in the literature [9]. PGHSs are formed by two monomers with a physically distinct COX and POX active site, respectively. While the two monomers bear different conformations, they function cooperatively during catalysis in solution. The half-of-sites binding to one monomer may cause the partner monomer to undergo a conformational change. This may in turn act to allosterically modulate cyclooxygenase catalysis in the partner monomer [10]. As such, inhibitors such as NSAIDs with different classes of structures may target COXs with respect to different levels of regulation of the activities of COX-1 and COX-2.

NSAIDs have not only been used to treat a wide variety of diseases with relatively limited side effects [11], but can also exert COX-independent activity [12]. Such an action may inhibit the production of proinflammatory cytokines [13]. For example, NLRP3 characterized as an inflammasome-forming pattern recognition receptor can induce a series of cascade mechanisms via activation and secretion of factors such as caspase-1. It leads to a final release of proinflammatory cytokine interleukin-1β (IL-1β) causing inflammatory storm and diseases. The NLRP3 inflammasome is associated with various disease formations including Alzheimer’s disease and atherosclerosis as well as type 2 diabetes. It therefore attracts attention for discovering potentially therapeutic inflammasome inhibitors. As an example, fenamate NSAIDs with a biaryl structure have been shown to inhibit IL-1β secretion [11]. Likewise, another biaryl compound, glyburide, with an intrachain and a sulfone group, also inhibits NLRP3 in spite of its main therapeutic indications toward type 2 diabetes [14].

Taken together, from the needs of both COX-2 and NLRP3 selective inhibitors against the threatening diseases, we are interested in generating the diversity of the fenbufen analogs [15–18]. Arising from NSAIDs with the biaryl ring structurally analogous to fenamate, we report here the construction of a derivatized biphenyl ring and their biological assays for inhibiting the activities of COX-2 and COX-1 and the release of IL-1β. More specifically, considering the structural elements of biphenyl, sulfone group and substituents on aromatic rings that are required for inhibiting both COX-2 and NLRP3, a facial construction of the biphenyl ring with halogen functionality and sulfone group on the aromatic ring would be a key to bridging the bioorganic chemistry in this field.

2. Results and Discussion

The previously described para-iodofenbufen is not a rational candidate for diversifying the biphenyl scaffold (Figure 1) [15]. On account of the multi-step syntheses required for introducing various substituents, an alternative route toward the biphenyl ring needs to be conceived.
iodofenbufen 1

Figure 1. Fenbufen analog as lead compound of this study.

A facial method is mediated through Suzuki Miyara (SM) coupling of one benzene ring that is derivatized from commercial source or self-preparation. The corresponding fenbufen derivatives 5a–5o were generated as shown in Scheme 1. Starting from bromobenzene via Friedel–Crafts acylation to introduce side chain 2, followed by borylation 3 [19], deprotection and the final SM coupling with the bromoarene derivatives, 15 fenbufen analogs can be generated [20–25]. Followed by further deprotection of the acid moiety, the final products 6a–6o were obtained [21,26–29].

Scheme 1. Preparation of the fenbufen analogs via Suzuki Miyara coupling reaction. Reaction conditions: (a) (i) Succinic anhydride, AlCl₃, CH₂Cl₂, r.t., 65 min, (ii) H₂SO₄, MeOH, r.t., 40 min; over two steps, 49%; (b) B₃PINO₂, KOAc, Pd(dppf)Cl₂, DMSO, 90 °C, 2 h, 78%; (c) NaIO₄, 1N HCl, THF/H₂O = 4:1, r.t., 2 h, 77%; (d) bromobenzene analogs, PdCl₂, K₂CO₃, EtOH/toluene = 1:1, r.t., 3–27 h, 31–93%; (e) CF₃COOH/H₂O, 110 °C, 2 h, 70–75%; LiOH/H₂O, r.t., 50%.

The above reactions are all performable with a rational total yield of 2–19% in five steps. Hydrolysis of the boronic ester 3 is a reversible reaction [30]. Although both stoichiometric amount and catalytic amount of 1 N HCl(aq) have been reported, only catalytic amount is capable of delivering an optimized yield in our hand. The byproduct pinacol is easily removed and the crude product after extraction can be forwarded to the subsequent reaction.

SM coupling is a well-known carbon-carbon formation reaction. It can be affected by the catalyst, base and solvent. The combination of Pd(PPh₃)₄ or Pd(PPh₃)₂Cl₂, Na₂CO₃ and dimethyloxyethane (DME) is mostly utilized [31]. When coupling the boronic acid 4...
and the bromo counterpart according to the common reaction condition, only 6% yield of fenbulen analog 5d was obtained (Table 1, entry 1). When trying other solvent and catalyst (entry 2) [32], we could merely observe the formation of the desired product 5d at 4 h but it faded away at 18.5 h post the reaction along with the presence of a more concentrated polar unknown byproduct. Even after an attempt to shorten the reaction time, the yield remains unsatisfactory (entry 3 and 4).

| Entry | Product | Catalyst | Base | Solvent | Time (h) | T (°C) | Yield (%) |
|-------|---------|----------|------|---------|----------|--------|-----------|
| 1     | 5d      | Pd(PPh3)4 (0.03 eq) | Na2CO3 (1.5 eq) | DME | 19 | 80 | 6 |
| 2     | 5d      | Pd(PPh3)2Cl2 (0.02 eq) | Na2CO3 (10 eq) | H2O | 18.5 | 70 | not observed |
| 3     | 5d      | Pd(PPh3)2Cl2 (0.02 eq) | Na2CO3 (10 eq) | H2O | 1.3 | 70 | 15 |
| 4     | 5d      | Pd(PPh3)2Cl2 (0.02 eq) | Na2CO3 (10 eq) | H2O | 0.5 | 80 | 25 |

Miyaura reported that basic condition may saponify the ester group, racemize chiral compounds and disable the condensation between aldehyde and alcohol [33]. Ester can be kept intact by employing a heterogeneous condition, such as the combination of aqueous K2CO3 and toluene, or the solid of K3PO4·nH2O or K2CO3 in toluene. While trying the condition of K2CO3, toluene and PdCl2 [34], reaction did not take place until the addition of a small amount of EtOH under assistance of a gradual increase of temperature to 75 °C from 90 min to 100 min post the reaction and a prolonged stirring overnight (entry 5). The isolated product fraction from flash chromatography was purified with HPLC to afford two fractions which were identified as a methyl ester 5b and an ethyl ester 5bbyp at a ratio of 1:1. The transesterification was not observed at the beginning of the reaction but it was observable after a cook. Thus, to prevent S-M coupling from the thermodynamic predominant transesterification, it needs to be stopped at 70 °C at 30 min post reaction in spite of a small amount of starting material remaining (entry 6). When substituting MeOH for EtOH, although the reaction proceeded rather fast, the yield did not improve.
significantly (entry 7). The optimized condition was met without transesterification when carried out at rt for 3 h (entry 8).

The SM coupling of the 1,2,4-tribromobenzene with organoboronic acid 4 generated three classes of products: tri-, di- and the major mono-coupled products. The fraction of mono coupled product mixtures from column chromatography could be further separated through HPLC to give three fractions at a yield ratio of 30:14:24 (Figure 2). As expected, the most steric hinderance C-2 decreases the yield of 5h. Compared to Pd(PPh3)4, the less bulky catalyst PdCl2 assist the SM coupling to all three positions [35]. The three compounds are distinguishable using 1H-NMR spectroscopy by comparing the deshielding effects arisen from the closeness to the two bromo groups [36].

![Figure 2. Sterically hindered C-2 position disfavors the SM coupling.](image)

In the course of the coupling, a homocoupled byproduct was always observed from TLC [30]. The byproduct did not really disturb the purification except the compound 5o. The polar NH2 group forms a hydrogen bond with SiO2. NEt3 as a common co-eluent for chromatography will render the current mobile phases inadequate because of deterioration of the theoretical plates. Only when substituting EtOAc/CH2Cl2/NEt3 or CH3OH/CH2Cl2/NEt3 with acetone/n-hexane/NEt3 = 2:8:0.3, a rough purification was allowed. However, the solubility remains an unresolved issue even after adding CHCl3; the mixture will gradually precipitate in the column chromatography resulting in blockade. Nevertheless, the homocoupled byproduct could be removed in the next tosylation. The final deprotection of the acid group could be accomplished using CF3COOH at 120 °C whereas NaOH in CH3OH (aq) is a common condition [19,37].

In view of the contribution of sulfonamide and sulfonylurea to the pharmacophore for inhibiting NLRP3 [13,38], e.g., MCC950 and glyburide [39,40], we therefore introduced a tolylsulfonyl group to mimic the pharmacophore (Scheme 2). Followed by tosylation and acid deprotection, the tosylate 8 was assessed for its bioactivity. To prevent the deprotected product from forming a TFA-co-crystalized complex that may alter the bioassay, LiOH was employed instead.

![Scheme 2. Preparation of fenbufen sulfonamide.](image)
The following compounds are also included in the bioassay (Figure 3). Compound 9 [41] and 10 were each obtained from the ester congeners that had been reported before [19]. Furthermore, compound 11 was obtained from its ester precursor 12 that was prepared in a similar S-M coupling. In contrast to the present organoboron laying on the arene already installed with a carboxylic acid group, the corresponding boron building block for compound 12 is on the other benzene moiety.

![Molecules 2022, 27, x FOR PEER REVIEW 6 of 40](image)

**Figure 3.** Additional fenbufen analogs involved in the present bioassays.

As shown in Figure 4, all the fenbufen analogs do not inhibit the release of IL-1 to a satisfactory level. The two rigid biaryl rings without a heteroatom to link between them may hamper the activity as evidenced from the NLRP-3 potent flufenamic acid encompassing an azo between two arenes [13]. The COX inhibition was assessed using the commercial assay kit Cayman (No. 560131). The whole assay procedure is divided into two parts: COX inhibition and ELISA staining. The detection by an enzyme-linked immune assay (ELISA) is aimed at comparing 20 compounds tested to the standard COX-2 selective celecoxib and COX-1 selective resveratrol in a qualitative manner. To assess their bioactivities simultaneously, the procedure was modified to fit the requirements for a minimal volume of 20 μL by each multipipetting. Visible light absorbance of both the groups of void COX and fully active COX are well within the meaningful ranges guided by the assay kit. In some batches of experiments, the reaction tube embedded in a holder makes heat transfer inefficient. Thus, the reaction temperature may be lower than the optimal 37 °C rendering the reaction incomplete, thus voiding the result. Hence, the current data is grouped on the basis of a comparison of compounds using concentration of 22 μM (Figures 5–7).

In general, all these fenbufen compounds are COX-2 selective (COX-2/COX-1 > 3). Some of them also show comparable COX-2 inhibition to that of celecoxib, such as the monosubstituted analogs *para*-fluoro 6a, *p*-hydroxy 6l and *p*-amino 6o analogs. The former two compounds show 8-fold inhibition of COX-2 compared to COX-1, whereas 6o shows 60-fold inhibition of COX-2 compared to COX-1. Concerning the disubstituted analogs, in spite of the high COX-2 selectivities by 6b, 6g, 6i and 6j, only 6b exhibits an acceptable COX-2 inhibition. Compound 6b contains one *ortho*-methyl as an electron-donating group and one *para*-fluoro as an electron-withdrawing group. The other three isosteres enclose both electron-withdrawing 4th periodic bromo groups. In addition, when encompassing two resonance-formable electron-donating groups, such as *o*- and *p*-dihydroxy compound 6m, the COX-2 selectivity diminishes while COX-2 activity is reasonable.
Figure 4. Fenbufen analogs at a concentration of 50 μM attested for their inhibition against IL1-β release.

Figure 5. COX-2 inhibition assay results. Compounds were tested at a concentration of 22 μM.
Figure 6. COX-1 inhibition assay results. Compounds were tested at a concentration of 22 μM.

Figure 7. COX-2 vs. COX-1 inhibition ratio by compounds 6i, 6j and 6o were greater than 60 due to their near-background COX-1-inhibition values.
Because of the substantial bioactivities of \( p \)-fluoro, \( p \)-hydroxy and \( p \)-amino fenbufen compounds \( 6a, 6l, 6o \), a further docking study was performed using in silico simulation and modeling. Two enzyme-sequence templates were retrieved from PDB bank encompassing COX-1 (1EQG) complexation with ibuprofen, a nonselective NSAID [42] and COX-2 (1CX2) complexation with SC558 (bromocelecoxib) [43], a COX-2 specific inhibitor. Before the molecular docking (MD) simulation, the receptor moieties, i.e., the two COX enzymes were both administered in the CHARMM force field throughout the whole docking process.

The flexible receptor atom property is enabled by creating a sphere radiating from a center defined by the PDB crystal data with a radius of 4 Å (Section 4.4.1) [42,43]. The two sites contain mostly involved residues including Arg120 and Tyr355 for COX-1 and His90, Gln192, Arg513, Ser353, Tyr355 and Phe518 for COX-2.

The in situ ligand minimization algorithm comprises a number of programmings, such as adopted basis Newton–Raphson (NR), steepest descent and conjugate gradient. NR is applied to a subspace of the coordinate vector spanned by the displacement coordinates of the last positions. Steepest descent and conjugate gradient are both used to improve a poor conformation through an iterative method via minimization steps as well as the current gradient to determine the next step. Energy minimization through these procedures will be scored in terms of the function of smart minimizer.

A further algorithm for generating conformations was enabled by adopting the option of FAST mode so that rational numbers of low-energy conformation were obtained at a reasonable of time cost. The entropy component for the ligand conformation was also optimized.

Because the solvent effect plays an important role in the binding calculation, an implicit solvent model was performed with respect to Coulomb repulsion and dielectric attraction using the mode of Poisson–Boltzmann with non-polar surface area (PBSA). PBSA is the most rigorous yet slowest solvent approximation method based on continuum electrostatics. A further scoring function, such as the salt concentration, was also addressed. For example, NaCl as the salt and concentration was set to be 0.145 M.

Through a preliminary flexible docking of COX-1 and COX-2, the fluoro analog \( 6a \) generated 36 and 30 docking poses, respectively; the hydroxy analog \( 6l \) generated 56 and 96 poses for each; the amino analog \( 6o \) provided 56 and 62 poses for each. According to the free energy derivation: 
\[
\Delta G_{\text{binding}} = \Delta G_{\text{complex}} - \Delta G_{\text{ligand}} - \Delta G_{\text{enzyme}}
\]
the top five high-scoring poses of each group were included in the binding free energy calculation and an average of the five data of each set are grouped in the Table 2. An exception is the fifth data of 5-hydroxy fenbufen \( 5l \) docked to COX-2 showing an extraordinarily large value which is skipped.

| Entry | Ligand                     | COX-1 (1EQG) Binding Energy (kcal/mol) | COX-2 (1CX2) Binding Energy (kcal/mol) | COX-2 Inhibition Percentage at 22 μM (%) |
|-------|----------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
| 1.    | celecoxib                  | \( \Delta G_{\text{CHARM}} \) b       | \( \Delta G_{\text{MM-PBSA}} \) c    | \( \Delta G_{\text{CHARM}} \) b       | \( \Delta G_{\text{MM-PBSA}} \) c    | 78.98 |
| 2.    | ibuprofen                  | -102.85                               | -0.46                                 | -127.06                               | -15.70                               | NP d |
| 3.    | \( p \)-fluorofenbufen \( 6a \) | -131.45                               | 2.542                                 | -156.22                               | -35.42                               | 74.02 |
| 4.    | \( p \)-hydroxyfenbufen \( 6l \) | -195.81                               | 34.65                                 | -248.78                               | 23.78                                 | 87.83 |
| 5.    | \( p \)-aminofenbufen \( 6o \) | -137.88                               | -4.77                                 | -166.05                               | -13.47                               | 71.92 |

a Free energy values are averaged from the 5 top high-scoring poses; b mode of binding free energy is derived from the whole system without incorporating the solvent term; c Mode of binding free energy is derived from the whole system by incorporating the solvent term; d not performable; e from docking to 4ph9; f derived from the average of 4 data sets, the last data of 13,934 is automatically skipped.
The current simulation was validated by redocking the benchmarking inhibitor ibuprofen to compare with the pose from the original crystallized COX-1 complex (1QEG) in the experimental (Section 4.4.4). The root-mean-square deviation (RMSD) value of 5.649 Å is larger than in the literature [44]. Similar findings were also observed in the case of redocking of celecoxib in comparison with the crystallographic pose of bromo analog (SC558) complexed with COX-2 (1CX2). Whereas the electron donating methyl group is virtually different from the electron withdrawing bromo group, the RMSD value of 6.615 Å is comparable to the example of ibuprofen.

The values of free binding energy ($\Delta G_{\text{binding-CHARMm}}$) from the first calculation ranging from $-60$ to $-250$ kcal/mol is smaller than the reported values of around $-10$ kcal/mol [44,45]. Calibration by incorporating the solvent term provides the second set of data ($\Delta G_{\text{binding-MMPBSA}}$). Whereas the $\Delta G_{\text{binding-MMPBSA}}$ of three compounds ($-13$ to $-35$ kcal/mol) are comparable to the literature, the two most COX-2 inhibiting $p$-hydroxy fenbufen 6l and celecoxib scoring poor in $\Delta G_{\text{binding-MMPBSA}} = 23$ kcal/mol seems to deviate unusually. The results may be due partly to the erroneous input of the original crystallized data of the 1eqg (COX-1) and 1CX2 (COX-2) at resolutions of 2.6 and 3.0 Å, respectively. The preliminary Gibbs free binding energy data under CHARMm condition provided a more consistent trend and formed the basis for comparison. It is noted that the COX-2 benchmarking inhibitor celecoxib scores are very low ($\Delta G_{\text{binding-CHARMm}} = -60$ kcal/mol) compared with fenbufen analogs ($-156$ to $-248$ kcal/mol). Fenbufen analogs may take advantage through the fitting feasibility of linear-like structural flexibility compared with the relatively rigid tri-cyclic structure of celecoxib.

The MD simulations of fluoro analog 6a with COX-1 and COX-2 show that both the long and narrow channels of the two active sites can accommodate fluoro analog 6a (Figures 8 and 9). Similar trends are also observed for the hydroxy and amino analogs 6l, 6o but are akin to bind more deeply in the active sites of COX-2 (Supplementary Materials Figures S1–S4). The free binding energy values of fluoro analog 6a to COX-2 are smaller but larger when docking to COX-1. This is also applicable to both the hydroxy and amino analogs 6l and 6o. Whereas van der Waals contacts between COX-1 and fluoro analog 6a constitute the major stabilization, unfavorable interactions are also emerged and even more than that of COX-2’s docking. Hydroxy analog 6l attains stabilization with both dockings of COX-1 and COX-2 in all respects of attractive interaction, such as the van der Waals and electrostatic interactions. Similar interaction patterns are observed in the case of amino analog 6o. The RMSD values for hydroxy and amino analogs 6l, 6o coupled with both enzymes are within reasonable ranges (COX-1 and COX2; 0.91 Å and 1.22 Å; 1.59 Å and 1.25 Å) except fluoro analog 6a, which shows relatively resonant values when docking to COX-1 (2.9 Å) but preserves reasonable values when docking to COX-2 (1.95 Å). In brief, the MD simulation results imply that the three compounds prefer a binding toward COX-2 than COX-1.

As shown in Table 2, while COX-2 inhibition by the benchmarking inhibitor celecoxib is comparable to the three fenbufen compounds, the stabilization predicted from the MD simulation is significantly less than that of the three fenbufen analogs. The mismatch may be caused by the fitting ability in terms of the geometric restrictions as described above. Nevertheless, the comparison among the three fenbufen analogs shows a dependency of the COX-2 activity on the MD simulation. For example, $p$-hydroxy fenbufen 6l scores the highest stabilization and exerts the most COX-2 inhibition. On the other hand, a similar finding was also observed in the group of $p$-fluoro and $p$-amino fenbufen analogs 6a, 6o but with an inverted order, probably due to the very close scoring and the close COX-2 inhibiting efficacy. As shown in Figure 10, the superimposition of $p$-hydroxy fenbufen 6l and COX-2 inhibitor bromocelecoxib (SC558) arranged themselves in a similar spatial orientation with a similar binding mode prevailing. Whereas the OH group of compound 6l exerts a prominent H-bonding to the OH group of Tyr385; the bromo group of SC558 lacks the corresponding interaction. The van der Waals contact between the aromatic ring of 6l and the nonpolar residues of Val 349 and Ala 527 enhances the stabilization. SC558
exerts a similar interaction but with extra stabilization through the two benzene rings. In addition, the polar groups of Arg 120, Arg 513 and His 90 can engage in the dipole-dipole attractions. The polar sulfone group of SC558 exerts similar interactions. In spite of the structural difference, they both follow a similar binding pattern which may address their equivalent COX-2 inhibition if the difference between bromo and methyl group in SC558 and celecoxib, respectively, could be neglected.

Figure 8. The 3-dimensional and 2-dimensional representations of the interaction of fluoro compound 6a with the active site of COX-1 enzyme (1EQG). The subunits responsible for interacting with compound 6a are labeled in color and the interactions are denoted by the dotted lines.
Figure 8. The 3-dimensional and 2-dimensional representations of the interaction of fluoro compound 6a with the active site of COX-1 enzyme (1EQG). The subunits responsible for interacting with compound 6a are labeled in color and the interactions are denoted by the dotted lines.

As shown in Table 2, while COX-2 inhibition by the benchmarking inhibitor celecoxib is comparable to the three fenbufen compounds, the stabilization predicted from the MD simulation is significantly less than that of the three fenbufen analogs. The mismatch may be caused by the fitting ability in terms of the geometric restrictions as described above. Nevertheless, the comparison among the three fenbufen analogs shows a dependency of the COX-2 activity on the MD simulation. For example, \( p \)-hydroxy fenbufen 6l scores the highest stabilization and exerts the most COX-2 inhibition. On the other hand, a similar finding was also observed in the group of \( p \)-fluoro and \( p \)-amino fenbufen analogs 6a, 6o but with an inverted order, probably due to the very close scoring and the close COX-2 inhibiting efficacy. As shown in Figure 10, the superimposition of \( p \)-hydroxy fenbufen 6l and COX-2 inhibitor bromocelecoxib (SC558) arranged themselves in a similar spatial orientation with a similar binding mode prevailing. Whereas the OH group of compound 6l exerts a prominent H-bonding to the OH group of Tyr385; the bromo group of SC558 lacks the corresponding interaction. The van der Waals contact between the aromatic ring of 6l and the nonpolar residues of Val 349 and Ala 527 enhances the stabilization. SC558 exerts a similar interaction but with extra stabilization through the two benzene rings. In addition, the polar groups of Arg 120, Arg 513 and His 90 can engage in the dipole-dipole attractions. The polar sulfone group of SC558 exerts similar interactions. In spite of the

Figure 9. The 3-dimensional and 2-dimensional representations of the interaction of fluoro compound 6a with the active site of COX-2 enzyme (1CX2). The subunits responsible for interacting with compound 6a are labeled in color and the interactions are denoted by the dotted lines.
structural difference, they both follow a similar binding pattern. The lowest free binding energy from the MD simulation by the tricyclic celecoxib analogs. The latter is related to the erroneous input and structural features. The former arises from fair crystallographic resolution of the model systems 1QEG and 1CX2 (2.6 Å and 3.0 Å). The latter is related to the erroneous input and structural features. The former arises from fair crystallographic resolution of the model systems 1QEG and 1CX2 (2.6 Å and 3.0 Å).

### 3. Conclusions

Through the Suzuki-Miyamura coupling reaction, a small library comprising 18 fenbufen compounds was generated. The optimized condition using PdCl$_2$ and the cosolvents of toluene and EtOH can generally provide the coupled biphenyl products within 3 h. In spite of insignificant IL-1β inhibition activity, the NSAIDs derivatives show a typical COX inhibition. As anticipated, the NLRP-3 activity might be improved by introducing a linker such as an azo or a sulfide group. Among them, $p$-fluoro, $p$-hydroxyl and $p$-amino fenbufen analogs 6a, 6l, 6o are better COX-2 inhibitors. The $p$-hydroxy fenbufen 6l is even better than celecoxib at the concentration level of 22 μM at COX-2 inhibition. All these potential fenbufen analogs exert a better inhibition against COX-2 than COX-1. The COX-2 potent and highly COX-2 selective $p$-amino fenbufen 6o needs to be further assessed for their inflammatory efficacy in vivo. The $p$-hydroxy fenbufen 6l showing the most COX-2 inhibition also deserves further study. Sulfone analog 8 shows potential because of having minor NLRP3 activity, a remarkable COX-2 activity and a considerable COX-2 selectivity.

MD simulation using CHARMM force field along with the parameter settings and validation of the program using benchmarking COX-2 inhibitor bromocelecoxib (SC58) and COX-1 inhibitor ibuprofen generates two classes of binding free energy scoring expression with respect to the solvent effects. Whereas the data from incorporating solvent effects biases the results, the preliminary CHARMM-derived data exerts a consistent trend and forms the basis for discussion. The relatively higher stabilization gained by the current simulation (−70 to −190 kcal) than the reported data (−10 kcal/mol) may be due to the erroneous input and structural features. The former arises from fair crystallographic resolution of the model systems 1QEG and 1CX2 (2.6 Å and 3.0 Å). The latter is related to the more feasibly structural flexibility exerted by the linear-like structural fenbufen than the tricyclic celecoxib analogs. The lowest free binding energy from the MD simulation by $p$-hydroxy fenbufen 6l was consistent with its highest COX-2 inhibiting activity. In addition, $p$-fluoro and $p$-amino fenbufen analogs 6a, 6o exert comparable experimental...
COX-2 inhibitions which are consistent with their equivalent free binding energies as predicted by $\Delta G_{\text{binding-CHARM}}$.

Both $p$-hydroxy fenbufen 6l and bromocelecoxib (SC558) follow the similar binding pattern to COX-2, irrespective of the difference between methyl group and bromo group.

4. Materials and Methods

4.1. General Information

Most reagents and solvents were purchased from Fluka (St. Louis, MO, USA), Sigma-Aldrich (St. Louis, MO, USA), Alfa (Binfield, Berkshire, UK), Acros (Geal, Belgium), Showa (Tokyo, Japan) or TCI (Tokyo, Japan). These compounds were performed in dried glassware under a purge of nitrogen at room temperature unless otherwise noted. CH$_2$Cl$_2$ and toluene were dried over CaH$_2$. CH$_3$OH was dried over Mg and distilled prior to reactions. THF was treated with FeSO$_4$·7H$_2$O and dried over KOH followed by filtration and distilled over Na. DMSO and DMF were distilled over CaH$_2$ under reduced pressure. NET$_3$ and pyridine were distilled over CaH$_2$. The related reagents and solvents were obtained in reagent grade. The eluents for flash chromatography (e.g., EtOAc, acetone, and $n$-hexane) were of industrial grade. They were distilled prior to use. CHCl$_3$ and CH$_3$OH were of reagent grade and used without purification. NMR spectroscopy including $^1$H-NMR (500 MHz) and $^{13}$C-NMR (125 MHz, DEPT-135) was performed by using a Unity Inova 500 MHz instrument (Varian, USA). Deuterated-solvents including CDCl$_3$, CD$_2$OD, C$_6$D$_6$ and DMSO-$d_6$ were purchased from Aldrich (St. Louis, MO, USA). Low-resolution mass spectrometry (LRMS) was carried out on an ESI-MS spectrometer using a Varian 901-MS Liquid Chromatography Tandem Mass Q-TOF Spectrometer at the Department of Chemistry of National Tsing-Hua University (NTHU). LRMS was also performed at the Department of Applied Chemistry of National Chiao-Tung University (NCTU). High-resolution mass spectrometry (HRMS) was carried out using a Varian HPLC (Prostar series ESI/APCI) system coupled with a Varian 901-MS (FT-ICR Mass) mass detector and a triple quadrupole setting. Thin layer chromatography (TLC) was performed with TLC silica gel 60 F$_{254}$ pre-coated plates (Machery-Nagel, Dueren, Germany) to monitor the starting materials and products upon visualization under UV light (254 nm). TLC plates were staining with either ninhydrin or ceric ammonium molybdate under heating. Celite 545 was obtained from Macherey-Nagel Inc. (Dueren, Germany). Strong acid cation exchange resin (H$^+$) was obtained from Amberlite IR-120. Column chromatography was performed using Silicycle 60 silica gel (60–200 mesh, Quebec City, QC, Canada) under a slight pressure. Melting points were measured with a MEL-TEMP instrument (Barnstead international, Dubuque, IA, USA) without correction.

Normal phase HPLC constitutes an Agilent isocratic 1100 pump that was connected by a UV-VIS detector (254 nm) and a column of ZORBAX SIL column (9.4 mm × 250 mm, 5 μm), a combination of EtOAc and $n$-hexane as the mobile phase at a flow rate of 3 mL/min. A Rheodyne injector with a loop of 0.5 mL was employed.

4.2. Chemical Preparation

\[ \text{para-Bromofenbufen methyl ester 2} \]

To a three-neck round bottomed flask was charged a mixture of succinic anhydride (31 g, 0.31 mol, 1.2 eq). CH$_2$Cl$_2$ (50 mL) was added and the mixture was stirred until dissolution. The mixture was cooled down by an ice bath followed by adding AlCl$_3$ (104 g, 0.78 mol, 3 eq). The bath was removed and bromobenzene (27 mL, 0.26 mol) was added. CH$_2$Cl$_2$ (50 mL) was added and the sticky solid was agitated using a spatula. The mixture...
was poured into a mixture containing ice (120 g) and HCl (12 N, 65 mL) followed by Büchner filtration through suction. The white residue was further concentrated under reduced pressure. While attempting to recrystallize by using CH₃OH for dissolution, a significant amount of methylated product was obtained but not to completeness. The mixture (35.5 g) after concentration under reduced pressure was submitted to an acid protection procedure as follows. The mixture was dried by distilling with toluene (10 mL) and CH₂Cl₂ (10 mL). CH₃OH (100 mL) and H₂SO₄ (7.5 mL) was added. Stirring was allowed for 40 min followed by extraction using EtOAc (200 mL), Na₂CO₃ (satd., 50 mL × 2). The organic layers were collected and dried over Na₂SO₄ followed by gravitational filtration. The filtrate was concentrated under reduced pressure to give 49% yield of the white solid (35 g, 0.13 mol) over two steps (m.p. 48–50 °C (lit.[46] m.p. 51.5 °C).

³¹P NMR (500 MHz, CDCl₃) δ 2.70 (t, J = 6.5 Hz, 2H, H₃Aliphatic), 3.21 (t, J = 6.7 Hz, 2H, H₃Aliphatic), 3.64 (s, 3H, HOCH₃), 7.54 (d, J = 8.0 Hz, 2H, HAr), 7.78 (d, J = 8.5 Hz, 2H, HAr); ¹³C NMR (125 MHz, CDCl₃).

δ 27.92 (aliphatic, CH₂), 33.33 (aliphatic, CH₂), 51.88 (OCH₃, CH₃), 128.43 (Ar, C), 129.55 (Ar, CH), 131.95 (Ar, CH), 135.24 (Ar, C), 173.22 (CO-OCH₃, C), 197.06 (Ar-CO, C).

3

A two-necked round-bottomed flask (50 mL) encompassing KOAc (7.3 g, 73.8 mmol, 4.0 eq) was dried in an oven at 120 °C for over 96 h. A second flask (50 mL) charging diboronpinacol (9.4 g, 36.9 mmol, 2.0 eq) was dried by distillation with toluene at 50 °C under reduced pressure. Bromo compound 2 (5.0 g, 18.5 mmol, 1 eq) was added and co-distilled with toluene. A spin-like flask (50 mL) containing a complex of dichloro-[1,1′-bis(diphenylphosphino)ferrocene] palladium (II) \([\text{PdCl}_2(dppf)]\) (500 mg, 0.68 mmol, 10.0% wt) was dried twice with toluene by co-distillation at 55 °C under reduced pressure. A flask containing dried DMSO (over 4 Å MS for 48 h) was bubbled with N₂ for 15 min. To the two-necked round bottomed flask containing KOAc, a mixture of bromo compound and diboronpinacol in DMSO (30 mL) and a solution of \(\text{PdCl}_2(dppf)\) in DMSO (10 mL) were added sequentially under sufficient stirring. The mixture was moved to an oil bath that had been preheated to 90 °C and the stirring was continued through bubbling. The mixture turned from light orange to dark brown after 10 min. TLC (EtOAc/n-hexane 2:8) indicated the consumption of the starting material 2 (Rf = 0.52) and formation of the product 3 (Rf = 0.52) with intense blue after staining. The reaction was terminated at 110 min post reaction by partitioning between CH₂Cl₂ (40 mL) and HCl (aq. 0.2 N, 20 mL). The organic layer was dried over MgSO₄ followed by filtration using a celite pad and concentration under reduced pressure. The black residue (25 g) contained a significant amount of DMSO that can be further reduced by a second extraction or purified through flash chromatography using the gradient mode of EtOAc/n-hexane 1:9 → 2:8 to give a pleasant Hinoki-essential oil-odor pale yellow viscous gum in a 78% yield (4.6 g).

³¹P NMR (500 MHz, CDCl₃) δ 1.33 (s, 12H, 4 × CH₃), 2.75 (t, J = 6.5 Hz, 2H, -CH₂), 3.31 (t, J = 6.5 Hz, 2H, -CH₂), 3.68 (s, 3H, -OCH₃), 7.87 (d, J = 8.0 Hz, 2H, aromatic), 7.93 (d, J = 8.0 Hz, 2H, aromatic); ¹³C NMR (125 MHz, CDCl₃) δ 24.86 (CH₃, Bpin) 28.01 (CH₂), 33.60 (CH₂), 51.81 (CH₃, O-CH₃), 84.21 (C, Bpin), 126.99 (CH, aromatic), 134.94 (CH, aromatic), 138.40 (C, aromatic), 173.33 (C, COO), 198.31 (C, CO).

4-(4-methoxy-4-oxobutanyloxy)phenylboronic acid 4
To a flask (100 mL) containing compound 3 (4.60 g, 14.4 mmol, 1 eq) was added THF (30 mL), H2O (7.5 mL) and NaO4 (9.20 g, 43.2 mmol, 3.0 eq), sequentially. After 10 min, 1N HCl (1.5 mL, 1.5 mmol, 0.1 eq) was added. The white precipitate was stirred for 2 h to show a complete consumption of starting material (Rf = 0.88) and formation of product (Rf = 0.40) from TLC (acetone/n-hexane = 5:5). The mixture was partitioned between EtOAc (30 mL) and Na2CO3 (10 mL), followed by washing with sat. NaCl(aq) (25 mL). The aqueous layers were further extracted with EtOAc (15 mL) × 3. The organic layers combined were dried over MgSO4 and filtered followed by concentration under reduced pressure to provide a white solid 4 (2.63 g, 77%). 148–153 °C.

1H-NMR (500 MHz, CDCl3/CD3OD = 1:1) δ 2.71 (t, J = 6.5 Hz, 2H, -CH2), 3.33 (t, J = 6.5 Hz, 2H, -CH2), 3.66 (s, 3H, -OCH3), 7.82 (d, 2H, aromatic), 7.92 (bs, J = 8.0 Hz, 2H, aromatic); 13C NMR (125 MHz, CDCl3/CD3OD = 1:1) δ 28.79 (CH2), 33.38 (CH2), 52.20 (CH3, O-CH3), 127.82 (CH, aromatic), 134.92 (CH, aromatic), 138.79 (C, aromatic), 140.47 (C, bs, Ar-BOH) 175.28 (C, CO); analysis for C11H13O5, calculated [M + Na]+ (m/z) = 259.0748 (100.0%), 258.0785 (24.8%), 260.0782 (9.7%), ESI-Q-TOF HR-ESI-MS found: [M + Na]+ = 259.0749 (46.6%), 258.0780 (11.2%), 260.0781 (5.8%), δ [ppm] = 0.4.

4-Boropinacol phenylmethanol

Reagents of commercial 4-bromophenyl methanol (2.0 g, 10.7 mmol, 1 eq), bis(pinacolato)diboron (5.4 g, 21.4 mmol, 2 eq), [PdCl2(dppf)] (200 mg, 10.0% wt) and KOAc (4.2 g, 42.8 mmol, 4 eq) as well as solvent DMF (20 mL) were used. Following the same procedure as that described for 3, the reaction was performed under reflux for 4 h. The mixture was filtered followed by concentration under reduced pressure using an oil pump. The residue was extracted using EtOAc (30 mL) and saline (15 mL × 3). The organic layer was collected, dried over Na2SO4 and filtered through celite. After concentrating the filtrate under reduced pressure, the crude product (2.3 g) was chromatographed using gradient mode of EtOAc/n-hexane 2:8 → 4:6 to give a pale yellow solid in 81% yield (2 g), analysis for C13H19BO3 m.p. 63–65 °C (lit.[47] m.p. 62–64 °C white powder, lit.[48] oil).

1H-NMR (500 MHz, CDCl3) δ 1.35 (s, 12H, H-Methyl), 4.72 (s, 2H, CH2), 7.37 (d, J = 7.5 Hz, 2H, HA), 7.80 (d, J = 8.0 Hz, 2H, HAr). 13C-NMR (125 MHz, CDCl3) δ 24.85 (methyl, CH3), 65.29 (OH-CH2, CH2), 83.80 (BPin, C), 126.06 (Ar, CH), 135.05 (Ar, CH), 143.95 (Ar, C).

Methyl 4-(4'-chloro-[1,1'-biphenyl]-4-yl)-4-oxobutanoate 5d
A flask charging K$_2$CO$_3$ (352 mg, 0.70 mmol, 3.1 eq) was dried at 120 °C for 48 h. The Erlenmeyer flask containing toluene (15 mL) and EtOH (15 mL) was bubbled thoroughly by N$_2$ for 15 min. To the cooled flask of K$_2$CO$_3$ was added the bubbled cosolvents (3 mL), the mixture of 4 (200 mg, 0.85 mmol, 1.0 eq) and 1-bromo-4-chlorobenzene (326 mg, 1.70 mmol, 2.0 eq) in cosolvents (5 mL) of EtOH and toluene and PdCl$_2$ (55 mg, 0.31 mmol, 6 mol%), sequentially. The mixture turned from red-brown to gray-black and finally to black in 1 h. The 3-h reaction indicated the consumption of the starting material 4 (R$_f$ = 0.20) and formation of the product (R$_f$ = 0.74) from TLC (acetone/n-hexane = 3/7). The mixture was extracted with 1 N HCl (0.2 mL), sat. NaCl(aq) (1.5 mL) and H$_2$O (5 mL), sequentially. The organic layer was washed with CH$_2$Cl$_2$ (6 mL) and sat. NaCl(aq) (1.5 mL). The organic layer along with the two organic layers used to back-extract the aqueous layer were dried over MgSO$_4$ and filtered. After concentration of the filtrate under reduced pressure, the white residue (693.1 mg) was chromatographed using EtOAc/n-hexane in a gradient mode of 1/9 → 2/8 → 3/7 to provide the white solid 5d in 77% yield (198 mg). m.p.: 117–120 °C.

$^1$H NMR (500 MHz, CDCl$_3$) $\delta$ 2.77 (t, $J$ = 6.5 Hz, 2H, -CH$_2$), 3.33 (t, $J$ = 6.5 Hz, 2H, -CH$_2$), 3.70 (s, 3H, -OCH$_3$), 7.41 (dd, $J$ = 7.0, 1.5 Hz, 2H, aromatic), 7.53 (dd, $J$ = 7.0, 1.5 Hz, 2H, aromatic), 7.63 (d, $J$ = 8.5 Hz, 2H, aromatic), 8.03 (d, $J$ = 8.5 Hz, 2H, aromatic); $^{13}$C NMR (125 MHz, CDCl$_3$) $\delta$ 28.03 (CH$_2$), 33.34 (CH$_2$), 51.80 (CH$_3$, O-CH$_3$), 127.09 (CH, aromatic), 128.48 (CH, aromatic), 128.71 (CH, aromatic), 132.13 (CH, aromatic), 134.48 (C, aromatic), 135.52 (C, aromatic), 135.95 (d, $J$ = 2.5 Hz, 2H, aromatic), 138.27 (C, aromatic), 144.58 (C, aromatic), 144.83 (C, aromatic), 153.27 (C, aromatic), 173.33 (C, COO), 173.32 (C, COO), 197.50 (C, CO); analysis for C$_{17}$H$_{15}$ClO$_3$ calculated [M + Na]$^+$ (m/z) = 325.0602 (100.0%), 327.0572 (32.0%), 326.0635 (18.4%), 328.0606 (5.9%), ESI-Q-TOF HR-ESI-MS found: [M + Na]$^+$ (m/z) = 325.0609 (100.0%), 327.0581 (30.9%), 326.0639 (15.9%), 328.0608 (5.1%), $\delta$ [ppm] = 2.1.

Reagents of 4 (52 mg, 0.21 mmol, 1.0 eq), bromo-4-fluorobenzene (73.5 mg, 0.42 mmol, 2.0 eq), K$_2$CO$_3$ (87 mg, 0.63 mmol, 3 eq) and PdCl$_2$ (14.5 mg, 0.08 mmol, 6 mol%) and cosolvents of toluene/EtOH = 1:1 (3 mL) were used. Followed the procedure for that of 5d for 3 h. TLC (acetone/n-hexane = 3/7) indicated the consumption of starting material (R$_f$ = 0.18) and formation of the product (R$_f$ = 0.52). The white solid of 5a was obtained in 82% yield (50 mg, 0.17 mmol). m.p.: 127–130 °C.

$^1$H NMR (500 MHz, CDCl$_3$) $\delta$ 2.77 (t, $J$ = 6.5 Hz, 2H, -CH$_2$), 3.32 (t, $J$ = 6.5 Hz, 2H, -CH$_2$), 3.70 (s, 3H, -OCH$_3$), 7.13 (ddd, $J$ = 11.0, 5.0, $J$ = 2.5 Hz, 2H, aromatic), 7.56 (ddd, $J$ = 11.0, 5.0, $J$ = 2.5 Hz, 2H, aromatic), 7.61 (d, $J$ = 8.5 Hz, 2H, aromatic), 8.00 (d, $J$ = 8.5 Hz, 2H, aromatic); $^{13}$C NMR (125 MHz, CDCl$_3$) $\delta$ 28.08 (CH$_2$), 33.34 (CH$_2$), 51.80 (CH$_3$, O-CH$_3$), 115.88 (d, $J_{CF}$ = 21.4 Hz, CH, aromatic), 127.07 (CH, aromatic), 128.66 (CH, aromatic), 128.89 (d, $J_{CF}$ = 8.1 Hz, CH, aromatic), 135.24 (C, aromatic), 136.95 (d, $J_{CF}$ = 2.8 Hz, C, aromatic), 143.83 (C, aromatic), 162.98 (d, $J_{CF}$ = 248.4 Hz, C, aromatic) 173.33 (C, COO), 197.52 (C, CO); analysis for C$_{17}$H$_{15}$FO$_3$ calculated [M + Na]$^+$ (m/z) = 309.0903 (100.0%), 310.0931 (18.4%), 311.0965 (1.6%), [2M + Na]$^+$ (m/z) = 595.1903 (100.0%), 596.1936 (36.8%).
597.1970 (6.6%), 597.1945 (1.2%), ESI-Q-TOF HR-ESI-MS found: [M + Na]+ = 309.0908 (75.0%), 310.0944 (14.2%), 311.0969 (1.22%), δ [ppm] = 1.8 [2M + Na]+ (m/z) = 595.1893 (100.0%), 596.1929 (36.8%), 597.1970 (37.2%), 597.1954 (8.9%), δ [ppm] = −1.7.

methyl 4-(4'-fluoro-2'-methyl-[1,1'-biphenyl]-4-yl)-4-oxobutan-2-0ic acid 5b, ethyl 4-(4'-fluoro-2'-methyl-[1,1'-biphenyl]-4-yl)-4-oxobutan-2-0ic acid 5bbyp

The reagents included 4 (52 mg, 0.21 mmol, 1.0 eq), 2-bromo-5-fluorotoluene (80 mg, 0.42 mmol, 2.0 eq), K2CO3 (87 mg, 0.63 mmol, 3 eq), PdCl2 (13 mg, 0.082 mmol, 6 mol%) and solvent of toluene (4 mL) and the procedure followed that of 5d. The reaction post 1 h remained pale brown and TLC (acetone/n-hexane = 3:7) indicated no consumption of starting material (Rf = 0.20). Additional EtOH (0.5 mL) was added and it turned gray and clear. After a further reaction at rt for 1.5 h, it was heated to 70–75 °C for 17.5 h. TLC (acetone/n-hexane = 3:7) indicated the formation of the two products (Rf = 0.68, 0.70). After chromatography, a plastic smell and viscous liquid of the mixture of 5b and 5bbyp (40 mg, 62%). The mixture was purified using HPLC with isocratic condition of EtOAc/n-hexane = 1:9 to give the methyl fenbufen analog 5b and ethyl fenbufen analog 5bbyp in a ratio of 1:1.

Another batch of experiment was optimized by using toluene/EtOH = 1:1 (3 mL) at 70 °C for 30 min. The viscous transparent liquid 5b was obtained in 75% yield (47 mg). 5b m.p.: 75–77 °C, 5bbyp m.p.: 51–53 °C.

methyl 4-(4'-fluoro-2'-methyl-[1,1'-biphenyl]-4-yl)-4-oxobutan-2-0ic acid 5b

1H NMR (500 MHz, CDCl3) δ 2.23 (s, 3H, Ar-CH3), 2.78 (t, J = 6.5 Hz, 2H, CH2), 3.34 (t, J = 6.5 Hz, 2H, CH2), 3.70 (s, 3H, O-CH3), 6.93 (t, J = 8.5, J = 2.5 Hz, 1H, aromatic), 6.97 (ddd, J = 9.5, J = 8.5, J = 2.5 Hz, 1H, aromatic), 7.15 (t, J = 8.5, J = 6.0 Hz, 1H, aromatic), 7.37 (d, J = 8.5 Hz, 2H, aromatic), 8.12 (d, J = 8.0 Hz, 2H, aromatic); 13C NMR (125 MHz, CDCl3) δ 20.51 (Ar-CH3), 28.05 (CH2), 33.41 (CH2), 51.84 (CH3, O-CH3), 112.77 (d, 2JCF = 21.2 Hz, CH, aromatic), 116.99 (d, 2JCF = 21.2 Hz, CH, aromatic), 128.00 (CH, aromatic), 129.57 (CH, aromatic), 130.97 (d, 3JCF = 8.5 Hz, CH, aromatic), 135.14 (C, aromatic), 136.72 (d, 4JCF = 2.5 Hz, C, aromatic), 137.63 (d, 3JCF = 7.9 Hz, C, aromatic), 146.12 (C, aromatic), 162.31 (d, 1JCF = 245.1 Hz, C, aromatic) 173.33 (C, aromatic), 172.92 (C, COO), 197.80 (C, CO); analysis for C18H17FO3, calculated [M + Na]+ (m/z) = 323.1054 (100.0%), 324.1087 (19.5%), 325.1115 (2.4%); ESI-Q-TOF HR-ESI-MS found: [M + Na]+ = 323.1058 (94.8%), 324.1086 (16.6%), 325.1115 (2.4%), δ [ppm] = −1.2.

ethyl 4-(4'-fluoro-2'-methyl-[1,1'-biphenyl]-4-yl)-4-oxobutan-2-0ic acid 5bbyp

1H NMR (500 MHz, CDCl3) δ 1.26 (t, J = 7.0 Hz, 3H, CH3), 2.23 (s, 3H, Ar-CH3), 2.77 (t, J = 6.5 Hz, 2H, CH2), 3.33 (t, J = 6.5 Hz, 2H, CH2), 4.16 (q, J = 7.0 Hz, 2H, O-CH2CH3), 6.93 (ddd, JHH = 8.5 Hz, JHF = 2.5 Hz, 1H, aromatic), 6.97 (ddd, J = 9.5, J = 8.5, J = 2.5 Hz, 1H, aromatic), 7.15 (t, J = 8.5, J = 6.0 Hz, 1H, aromatic), 7.37 (d, J = 8.5 Hz, 2H, aromatic), 8.09 (d, J = 8.0 Hz, 2H, aromatic); 13C NMR (125 MHz, CDCl3) δ 14.19 (CH3, O-CH2CH3), 20.51 (Ar-CH3), 28.33 (CH2), 33.41 (CH2), 60.68 (CH2, O-CH2CH3), 112.76 (d, 2JCF = 20.9 Hz, CH, aromatic), 116.98 (d, 2JCF = 21.3 Hz, CH, aromatic), 128.00 (CH, aromatic), 129.57 (CH, aromatic), 130.97 (d, 3JCF = 8.5 Hz, CH, aromatic), 135.20 (C, aromatic), 136.73 (d, 4JCF = 2.3 Hz, C, aromatic), 137.63 (d, 3JCF = 7.9 Hz, C, aromatic), 146.07 (C, aromatic), 162.30 (d, 1JCF = 245.1 Hz, C, aromatic) 172.92 (C, COO), 197.80 (C, CO); analysis for C19H19FO3, calculated [M + Na]+ (m/z) = 337.1210 (100.0%), 338.1244 (20.5%), 339.1278 (2.0%); ESI-Q-TOF HR-ESI-MS found: [M + Na]+ = 337.1209 (100.0%), 338.1236 (16.8%), 339.1268 (2.3%), δ [ppm] = −0.3.

methyl 4-(2',4'-difluoro-[1,1'-biphenyl]-4-yl)-4-oxobutan-2-0ic acid 5c
Reagents of 4 (200 mg, 0.85 mmol, 1 eq), 1-bromo-2, 4-difluorobenzene (328 mg, 1.70 mmol, 2 eq), K$_2$CO$_3$ (352 mg, 2.55 mmol, 3 eq) and PdCl$_2$ (55 mg, 0.31 mmol, 6 mol%) and cosolvents of toluene/ETOH = 1:1 (7.5 mL) were used. Following the procedure for that of 5d for 3 h. TLC (EtOAc/n-hexane = 4/6) indicated the consumption of starting material (R$_f$ = 0.20) and formation of the product (R$_f$ = 0.72). The white solid of 5e was obtained in 69% yield (176 mg, 0.58 mmol). m.p.: 77–78 °C.

$^1$H NMR (500 MHz, CDCl$_3$) $\delta$ 2.78 (t, $J$ = 6.5 Hz, 2H, CH$_2$), 3.33 (t, $J$ = 6.5 Hz, 2H, CH$_2$), 3.70 (s, 3H, OCH$_3$), 6.92 (td, $J$ = 9.0, $J$ = 2.5 Hz, 1H, aromatic), 6.96 (dd, $J$ = 8.5, $J$ = 2.5 Hz, 1H, aromatic), 7.41 (td, $J$ = 8.5, $J$ = 6.0 Hz, 1H, aromatic), 7.59 (d, $J$ = 8.5, $J$ = 2.0 Hz, 2H, aromatic), 8.03 (d, $J$ = 8.5 Hz, 2H, aromatic); $^{13}$C NMR (125 MHz, CDCl$_3$) $\delta$ 28.03 (CH$_2$), 33.44 (CH$_2$), 51.83 (CH$_3$, O-CH$_3$), 104.61 (t, $J_{CF}$ = 25.8 Hz, CH, C-3$^\prime$), 111.85 (dd, $J_{CF} = 21.0$ Hz, $J_{HF} = 3.8$ Hz, CH, C-5$^\prime$), 124.18 (dd, $J_{CF} = 13.4$ Hz, $J_{HF} = 3.8$ Hz, C, C-1$^\prime$) 128.27 (CH, aromatic), 129.10 (d, $J_{CF} = 2.8$ Hz, CH, aromatic), 131.39 (dd, $J_{CF} = 9.6$ Hz, $J_{CF} = 4.6$ Hz, CH, C-6$^\prime$), 135.63 (C, aromatic), 139.80 (C, aromatic), 159.79 (dd, $J_{CF} = 250.1$ Hz, $J_{CF} = 12.5$ Hz, C-F, C-2$^\prime$), 162.82 (dd, $J_{CF} = 249.0$ Hz, $J_{CF} = 12.5$ Hz, C-F, C-4$^\prime$), 173.31 (C, COO), 197.55 (C, CO); analysis for C$_{17}$H$_{14}$F$_2$O$_3$, calculated [M + Na]$^+$ ($m/z$) = 328.0803 (100.0%), 328.0837 (18.4%), 329.0870 (1.6%), ESI-Q-TOF HR-ESI-MS found: [M + Na]$^+$ = 327.0802 (96.2%), 328.0835 (17.0%), 329.0868 (2.3%), $\delta$ [ppm] = 1.5.

methyl 4-(4′-chloro-2′-methyl-[1,1′-biphenyl]-4-yl)-4-oxobutanoate 5e

Reagents of 4 (52 mg, 0.21 mmol, 1.0 eq), 2-bromo-5-chlorotoluene (86 mg, 0.42 mmol, 2.0 eq), K$_2$CO$_3$ (96 mg, 0.70 mmol, 3.3 eq) and PdCl$_2$ (13 mg, 0.082 mmol, 6 mol%) and cosolvents of toluene/CH$_3$OH = 1:1 (3 mL) were used. Following the procedure for that of 5d for 3 h. TLC (acetone/n-hexane = 3:7) indicated the consumption of starting material (R$_f$ = 0.20) and formation of the product (R$_f$ = 0.62). The white solid of 5e was obtained in 71% yield (46 mg, 0.15 mmol). m.p.: 77–78 °C.

$^1$H NMR (500 MHz, CDCl$_3$) $\delta$ 2.22 (s, 3H, Ar-CH$_3$), 2.78 (t, $J$ = 6.5 Hz, 2H, CH$_2$), 3.30 (t, $J$ = 6.5 Hz, 2H, CH$_2$), 3.70 (s, 3H, O-CH$_3$), 7.12 (d, $J$ = 8.5 Hz, 1H, aromatic), 7.21 (d, $J$ = 8.5, $J$ = 2.0 Hz, 1H, aromatic), 7.26 (s, 1H, aromatic), 7.37 (d, $J$ = 8.5 Hz, 2H, aromatic), 8.01 (d, $J$ = 8.5 Hz, 2H, aromatic); $^{13}$C NMR (125 MHz, CDCl$_3$) $\delta$ 20.25 (Ar-CH$_3$), 28.02 (CH$_2$), 33.40 (CH$_2$), 51.81 (CH$_3$, O-CH$_3$), 126.02 (CH, aromatic), 128.02 (CH, aromatic), 129.39 (CH, aromatic), 130.32 (CH, aromatic), 130.68 (CH, aromatic), 133.59 (C, aromatic), 135.27 (C-Cl, aromatic), 137.08 (C, aromatic), 139.16 (C, aromatic), 145.83 (C, aromatic) 173.32 (C, COO), 197.63 (C, CO); analysis for C$_{18}$H$_{17}$ClO$_3$, calculated [M + H]$^+$ ($m/z$) = 317.0946 (100.0%), [M + Na]$^+$ ($m/z$) = 339.0764 (100.0%), 341.0729 (32.0%), 340.0792 (19.5%), ESI-Q-TOF HR-ESI-MS found: [M + H]$^+$ ($m/z$) = 317.0942 (12.7%), $\delta$ [ppm] = −0.8, [M + Na]$^+$ = 339.0766 (100.0%), 341.0743 (38.5%), 340.0786 (25.9%), $\delta$ [ppm] = 0.6.

methyl 4-(2′,4′-dichloro-[1,1′-biphenyl]-4-yl)-4-oxobutanoate 5f
Reagents of 4 (200 mg, 0.85 mmol, 1 eq), 1-bromo-2, 4-dichlorobenzene (384 mg, 1.70 mmol, 2 eq), K₂CO₃ (352 mg, 2.55 mmol, 3 eq) and PdCl₂ (55 mg, 0.31 mmol, 6 mol%) and cosolvents of toluene/EtOH = 1:1 (7.5 mL) were used. Following the procedure for that of 5d for 27 h. TLC (EtOAc/n-hexane = 4/6) indicated the consumption of starting material (Rₛ = 0.20) and formation of the product (Rₛ = 0.76). The white solid of 5f was obtained in 69% yield (197 mg, 0.58 mmol).

₁H NMR (500 MHz, CDCl₃) δ 2.22 (s, 3H, Ar-CH₃), 2.78 (t, J = 6.5 Hz, 2H, CH₂), 3.29 (t, J = 6.5 Hz, 2H, CH₂), 3.65 (s, 3H, -OCH₃), 7.20 (dd, J = 8.5, 2.0 Hz, 1H, aromatic), 7.26 (dd, J = 8.5, 2.0 Hz, 1H, aromatic), 7.45 (dd, J = 7.0, 2.0 Hz, 3H, aromatic), 7.98 (dd, J = 7.0, 2.0 Hz, 2H, aromatic); ¹³C NMR (125 MHz, CDCl₃) δ 28.00 (CH₂), 33.46 (CH₂), 51.83 (O-CH₃), 127.33 (CH, aromatic), 127.94 (CH, aromatic), 129.69 (CH, aromatic), 129.91 (CH, aromatic), 131.81 (CH, aromatic), 133.08 (C-Cl, aromatic), 134.48 (C-Cl, aromatic), 135.80 (C, aromatic), 137.90 (C, aromatic), 143.09 (C, aromatic), 174.04 (C, COO), 198.44 (C, CO); analysis for C₁₇H₁₄Br₂O₃, calculated [M + Na]⁺ (m/z) = 359.0212 (100.0%), 361.0183 (63.9%), 362.0264 (14.8%), 362.0216 (11.8%), 363.0153 (10.2%), ESI-Q-TOF HR-ESI-MS found: [M + Na]⁺ = 359.0212 (88.1%), 361.0185 (60.0%), 362.0220 (10.8%), 363.0158 (10.3%), δ [ppm] = 0.

methyl 4-(3′,4′-dibromo-[1,1′-biphenyl]-4-yl)-4-oxobutanoate 5g, methyl 4-(2′,5′-dibromo-[1,1′-biphenyl]-4-yl)-4-oxobutanoate 5h, methyl 4-(2′,4′-dibromo-[1,1′-biphenyl]-4-yl)-4-oxobutanoate 5i

Reagents of 4 (200 mg, 0.85 mmol, 1 eq), 1, 2, 4-tribromobenzene (535 mg, 1.70 mmol, 2 eq), K₂CO₃ (352 mg, 2.55 mmol, 3 eq) and PdCl₂ (55 mg, 0.31 mmol, 6 mol%) and cosolvents of toluene/EtOH = 1:1 (7.5 mL) were used. Following the procedure that for 5d for 2 h. TLC (EtOAc/n-hexane = 3/7) indicated the consumption of starting material (Rₛ = 0.20) and formation of the product (Rₛ = 0.54–0.64). The white solid was obtained as a mixture in 68% yield (246 mg). A portion of the sample (50 mg) was analyzed using normal phase HPLC per isocratic mode with eluents of EtOAc/n-hexane = 1/10 to give white solid 5g, viscous liquid 5h and white solid 5i in 30% (20 mg), 14% (9 mg) and 24% (16 mg) yield,
respectively. Due to the limited amount of 5h, spectroscopic measurement was not taken. It was directly deprotected for subsequent spectroscopic analysis and biological assay.

methyl 4-(3',4',5'-tribromo-[1,1'-biphenyl]-4-yl)-4-oxobutanoate 5g

1H NMR (500 MHz, CDCl3) δ 2.77 (t, J = 6.5 Hz, 2H, CH2), 3.32 (t, J = 6.5 Hz, 2H, CH2), 3.70 (s, 3H, -OCH3), 7.38 (d, J'γγ = 8.5 Hz, H'γγ = 2.0 Hz, 1H, aromatic), 7.61 (d, J = 8.5 Hz, 2H, aromatic), 7.68 (d, J = 8.5 Hz, 2H, aromatic), 7.84 (s, J'γ = 2.0 Hz, 1H, aromatic), 8.03 (d, J = 8.5 Hz, 2H, aromatic). 13C NMR (125 MHz, CDCl3) δ 28.00 (CH2), 33.47 (CH2), 51.83 (C-Br, aromatic), 124.78 (C-Br, aromatic), 125.47 (C-Br, aromatic), 127.10 (CH, aromatic), 127.21 (CH, aromatic), 128.78 (CH, aromatic), 132.23 (CH, aromatic), 134.07 (CH, aromatic), 135.97 (C, aromatic), 140.55 (C, aromatic), 173.28 (C, COO); analysis for C17H14Br2O3, calculated [M + Na]+ (m/z) = 448.9181 (100.0%), 446.9207 (51.4%), 450.9161 (48.6%), 449.9215 (9.7%), 451.9195 (8.9%), ESI-Q-TOF HR-ESI-MS found: [M + Na]+ = 448.9183 (100.0%), 446.9204 (78.7%), 450.9177 (81.2%), 449.9230 (32.8%), 451.9214 (1.3%), δ [ppm] = 0.4.

methyl 4-(2',5',6'-tribromo-[1,1'-biphenyl]-4-yl)-4-oxobutanoate 5h

1H NMR (500 MHz, CDCl3) δ 2.78 (t, J = 6.5 Hz, 2H, CH2), 3.34 (t, J = 6.5 Hz, 2H, CH2), 3.70 (s, 3H, -OCH3), 7.35 (d, J'γγ = 8.5 Hz, J'γ = 2.5 Hz, 1H, aromatic), 7.44 (s, J' = 2.5 Hz, 1H, aromatic), 7.47 (d, J = 8.5 Hz, 2H, aromatic), 7.52 (d, J = 8.5 Hz, 2H, aromatic), 8.03 (d, J = 8.5 Hz, 2H, aromatic). 13C NMR (125 MHz, CDCl3) δ 28.01 (CH2), 33.50 (CH2), 51.85 (CH3, O-CH3), 120.94 (C-Br, aromatic), 121.32 (C-Br, aromatic), 127.93 (CH, aromatic), 129.60 (CH, aromatic), 132.30 (CH, aromatic), 133.66 (CH, aromatic), 134.61 (CH, aromatic), 135.99 (CH, aromatic), 143.25 (C, aromatic), 144.48 (C, aromatic), 173.30 (C, COO), 197.55 (C, CO); analysis for C17H14Br2O3, calculated [M + Na]+ (m/z) = 448.9181 (100.0%), 446.9207 (51.4%), 450.9161 (48.6%), 449.9215 (9.7%), 451.9195 (8.9%), ESI-Q-TOF HR-ESI-MS found: [M + Na]+ = 448.9187 (100.0%), 446.9207 (57.1%), 450.9177 (54.2%), 449.9205 (27.7%), 451.9360 (2.1%), 447.9314 (3.4%), δ [ppm] = 1.3.

methyl 4-(2',4',5'-tribromo-[1,1'-biphenyl]-4-yl)-4-oxobutanoate 5j

1H NMR (500 MHz, CDCl3) δ 2.78 (t, J = 6.5 Hz, 2H, -CH2), 3.38 (t, J = 6.5 Hz, 2H, CH2), 7.17 (d, J = 8.0 Hz, 1H, aromatic), 7.46 (d, J = 8.0 Hz, 2H, aromatic), 7.50 (d, J'γγ = 8.0 Hz, J'γ = 2.0 Hz, 1H, aromatic), 7.84 (s, J'γ = 2.0 Hz, 1H, aromatic), 8.03 (d, J = 8.0 Hz, 2H, aromatic). 13C NMR (125 MHz, CDCl3) δ 28.02 (CH2), 33.48 (CH2), 51.84 (CH3, O-CH3), 122.32 (C-Br, aromatic), 122.89 (C-Br, aromatic), 127.91 (CH, aromatic), 129.59 (CH, aromatic), 130.73 (CH, aromatic), 131.94 (CH, aromatic), 135.60 (CH, aromatic), 135.86 (CH, aromatic), 140.46 (C, aromatic), 144.78 (C, aromatic), 173.29 (C, COO), 197.56 (C, CO).

methyl 4-(3',5',6'-tribromo-[1,1'-biphenyl]-4-yl)-4-oxobutanoate 5k

Reagents of 4 (200 mg, 0.85 mmol, 1 eq), 1-bromo-2, 4-difluorobenzene (538 mg, 1.70 mmol, 2 eq), K2CO3 (352 mg, 2.55 mmol, 3 eq) and PdCl2 (55 mg, 0.31 mmol, 6 mol%) and cosolvents of toluene/EtOH = 1:1 (7.5 mL) were used. Following the procedure for that of 5d for 3 h. TLC (EtOAc/n-hexane = 4/6) indicated the consumption of starting material (Rf = 0.40) and formation of the product (Rf = 0.72). The white solid of 5j was obtained in 36% yield (141 mg, 0.31 mmol). m.p.: 107–108 °C.

1H NMR (500 MHz, CDCl3) δ 2.78 (t, J = 6.5 Hz, 2H, CH2), 3.33 (t, J = 6.5 Hz, 2H, CH2), 3.70 (s, 3H, -OCH3), 7.60 (d, J = 8.5 Hz, 2H, aromatic), 7.66 (dd, J = 9.0, 1.0 Hz, 3H, aromatic), 8.04 (d, J = 8.5 Hz, 2H, aromatic). 13C NMR (125 MHz, CDCl3) δ 28.00 (CH2), 33.50 (CH2),...
51.86 (CH₃, O-CH₃), 123.47 (C-Br, aromatic), 127.33 (CH, aromatic), 128.78 (CH, aromatic), 129.09 (CH, aromatic), 133.52 (CH, aromatic), 136.24 (C, aromatic), 142.80 (C, aromatic), 143.39 (C, aromatic), 173.28 (C, COO), 197.41 (C, CO); analysis for C₁₇H₁₄Br₂O₃, calculated [M + Na]⁺ (m/z) = 448.9187 (100.0%), 446.9207 (51.4%), 450.9161 (48.6%), 449.9215 (9.7%), 451.9193 (8.9%), ESI-Q-TOF HR-ESI-MS found: [M + Na]⁺ = 448.9192 (25.8%), 446.9194 (13.7%), 450.9177 (12.8%), 449.9228 (4.8%), 451.9183 (2.8%), δ [ppm] = −2.4.

methyl 4-(4′-acetyl-[1,1′-biphenyl]-4-y)-4-oxobutanoate 5k

Reagents of 4 (200 mg, 0.85 mmol, 1 eq), 4-bromoacetophenone (338.4 mg, 1.70 mmol, 2 eq), K₂CO₃ (352 mg, 2.55 mmol, 3 eq) and PdCl₂ (55 mg, 0.31 mmol, 6 mol%) and cosolvents of toluene/EtOH = 1:1 (7.5 mL) were used. Following the procedure for that of 5d for 1 h. TLC (acetone/n-hexane = 3/7) indicated the consumption of starting material (Rf = 0.18) and formation of the product (Rf = 0.40). The mixture was chromatographed using eluents of CH₃OH/CH₂Cl₂ = 1/99 to provide the white solid 5k in 81% yield (215 mg, 0.69 mmol). 151–158 °C.

³H NMR (500 MHz, CDCl₃) δ 2.62 (s, 3H, Ar-COCH₃), 2.78 (t, J = 6.5 Hz, 2H, Ar-COCH₂), 3.33 (t, J = 6.5 Hz, 2H, CH₂), 3.70 (s, 3H, COOCH₃), 7.69 (d, J = 8.0 Hz, 2H, aromatic), 7.70 (d, J = 8.5 Hz, 2H, aromatic), 8.03 (d, J = 8.0 Hz, 2H, aromatic), 8.06 (d, J = 8.5 Hz, 2H, aromatic); ¹³C NMR (125 MHz, CDCl₃) δ 26.63 (CH₃, COCH₃), 27.99 (CH₂), 33.45 (CH₂), 51.81 (CH₃, O-CH₃), 127.40 (CH, aromatic), 127.44 (CH, aromatic), 128.70 (CH, aromatic), 128.96 (CH, aromatic), 135.96 (C, aromatic), 136.57 (C, aromatic), 144.26 (C, aromatic), 144.23 (C, aromatic), 173.28 (C, COO), 197.51 (C, CO); analysis for C₁₉H₁₈O₄, calculated [M + Na]⁺ (m/z) = 333.1103 (100.0%), 334.1142 (22.46%), δ [ppm] = 0.4.

methyl 4-(4′-hydroxy-[1,1′-biphenyl]-4-y)-4-oxobutanoate 5l

Reagents of 4 (200 mg, 0.85 mmol, 1 eq), 4-bromophenol (294 mg, 1.70 mmol, 2 eq), K₂CO₃ (352 mg, 2.55 mmol, 3 eq) and PdCl₂ (55 mg, 0.31 mmol, 6 mol%) and cosolvents of toluene/EtOH = 1:1 (6 mL) were used. Following the procedure for that of 5d for 5 h. TLC (acetone/n-hexane = 3/7) indicated the consumption of starting material (Rf = 0.14) and formation of the product (Rf = 0.24). The mixture was chromatographed using eluents of CH₃OH/CH₂Cl₂ in a gradient mode of 1/99 → 1/49 → 1/19 to provide the white solid 5l in 90% yield (214 mg, 0.75 mmol). m.p.: 179–182 °C.

³H NMR (500 MHz, CDCl₃/CD₃OD = 1:1) δ 2.72 (t, J = 6.5 Hz, 2H, CH₂), 3.32 (t, J = 6.5 Hz, 2H, CH₂), 3.67 (s, 3H, O-CH₃), 6.87 (d, J = 8.5 Hz, 2H, aromatic), 7.47 (d, J = 8.5 Hz, 2H, aromatic), 7.61 (d, J = 8.5 Hz, 2H, aromatic), 7.97 (d, J = 8.5 Hz, 2H, aromatic); ¹³C NMR (125 MHz, CDCl₃/CD₃OD = 1:1) δ 28.61 (CH₂), 33.86 (CH₂), 52.18 (CH₃, O-CH₃), 116.40 (CH, aromatic), 126.99 (CH, aromatic), 128.92 (CH, aromatic), 129.20 (CH, aromatic), 131.61 (C, aromatic), 134.90 (C, aromatic), 146.70 (C, aromatic), 158.26 (C-OH, aromatic), 174.62 (C, COO), 199.26 (C, CO); analysis for C₁₇H₁₆O₄, calculated [M + Na]⁺ (m/z) =
Reagents of 4 (400 mg, 1.69 mmol, 1 eq), 4-bromoresorcinol (642 mg, 3.40 mmol, 2 eq), K₂CO₃ (705 mg, 5.10 mmol, 3 eq) and PdCl₂ (110 mg, 0.62 mmol, 6 mol%) and cosolvents of toluene/EtOH = 1:1 (4.5 mL) were used. Following the procedure for that of 5d for 19 h. TLC (CH₂OH/CH₂Cl₂ = 1/19) indicated the consumption of starting material (Rₛ = 0.66) and formation of the product (Rₛ = 0.50). The mixture was chromatographed using eluents of CH₂OH/CH₂Cl₂ = 1/29 to provide the impure brown solid 5m in 63% crude yield (321 mg, 1.07 mmol). A portion (110 mg) was purified using HPLC with eluents of CH₂OH/CH₂Cl₂ = 1/49 to afford a white solid of 5m in 31% yield (55 mg). m.p.: 82–86 °C.

¹H NMR (500 MHz, CDCl₃/CD₃OD = 1:1) δ 2.72 (t, J = 6.5 Hz, 2H, CH₂), 3.33 (t, J = 6.5 Hz, 2H, CH₂), 3.67 (s, 3H, -OCH₃), 6.40 (d, J = 7.5 Hz, 2H, aromatic), 7.12 (d, J = 8.5, 1H, aromatic), 7.65 (d, J = 8.5 Hz, 2H, aromatic), 7.94 (d, J = 8.5 Hz, 2H, aromatic); ¹³C NMR (125 MHz, CDCl₃/CD₃OD = 1:1) δ 28.70 (CH₂), 33.67 (s, 3H, -OCH₃), 6.40 (d, J = 7.5 Hz, 2H, aromatic), 7.12 (d, J = 8.5, 1H, aromatic), 7.65 (d, J = 8.5 Hz, 2H, aromatic), 7.94 (d, J = 8.5 Hz, 2H, aromatic); ¹³C NMR (125 MHz, CDCl₃/CD₃OD = 1:1) δ 28.70 (CH₂), 33.67 (s, 3H, -OCH₃), 6.40 (d, J = 7.5 Hz, 2H, aromatic), 7.12 (d, J = 8.5, 1H, aromatic), 7.65 (d, J = 8.5 Hz, 2H, aromatic), 7.94 (d, J = 8.5 Hz, 2H, aromatic).

methyl 4-(2′,4′-dihydroxy-[1,1′-biphenyl]-4-yl)-4-oxobutanoate 5m

Reagents of 4 (200 mg, 0.85 mmol, 1 eq), 4-bromo-4-nitrobenzene (343.4 mg, 1.70 mmol, 2 eq), K₂CO₃ (352 mg, 2.55 mmol, 3 eq) and PdCl₂ (55 mg, 0.31 mmol, 6 mol%) and cosolvents of toluene/EtOH = 1:1 (7.5 mL) were used. Following the procedure for that of 5d for 30 min. TLC (acetone/n-hexane = 3/7) indicated the consumption of starting material (Rₛ = 0.20) and formation of the product (Rₛ = 0.50). The white solid of 5n was obtained in 93% yield (248 mg, 0.79 mmol). m.p.: 146–150 °C.

¹H NMR (500 MHz, CDCl₃) δ 2.79 (t, J = 6.5 Hz, 2H, -CH₂), 3.34 (t, J = 6.5 Hz, 2H, -CH₂), 3.70 (s, 3H, -OCH₃), 7.20 (d, J = 8.5 Hz, 2H, aromatic), 7.75 (d, J = 8.5 Hz, 2H, aromatic), 8.08 (d, J = 8.5 Hz, 2H, aromatic), 8.30 (d, J = 8.5 Hz, 2H, aromatic); ¹³C NMR (125 MHz, CDCl₃) δ 27.97 (CH₂), 33.51 (CH₂), 51.86 (CH₃, O-CH₃), 124.20 (CH, aromatic), 127.64 (CH, aromatic), 128.07 (CH, aromatic), 128.85 (CH, aromatic), 136.52 (C, aromatic), 143.22 (C, aromatic), 146.16 (C, aromatic), 147.65 (C-NO₂, aromatic), 173.26 (C, COO), 197.43 (C, CO); analysis for C₁₇H₁₃NO₅, calculated [M + Na⁺] (m/z) = 336.0848 (100.0%), 337.0876 (18.4%).
methyl 4-(4′-amino-[1,1′-biphenyl]-4-yl)-4-oxobutanoate 5o

Reagents of 4 (400 mg, 1.69 mmol, 1 eq), 4-bromoaniline (581 mg, 3.38 mmol, 2 eq), K$_2$CO$_3$ (796 mg, 5.04 mmol, 3 eq) and PdCl$_2$ (110 mg, 0.62 mmol, 6 mol%) and cosolvents of toluene/EtOH = 1:1 (6 mL) were used. Following the procedure for that of 5d for 6 h. TLC (acetone/n-hexane = 3/7) indicated the consumption of starting material (R$_f$ = 0.22) and formation of the product (R$_f$ = 0.26). The mixture was chromatographed using eluents of acetone/n-hexane/Et$_3$N = 2/8/0.3. However, the crude mixture was not dissolved and precipitated in column. After a rough elution of most 4-bromoaniline and a small part of the product, the eluents were changed as EtOAc/Et$_3$N = 10/0.3 to dissolve the precipitates. After concentration under reduced pressure, a yellow impure solid was obtained in a quantitative yield (454 mg). m.p.: 94–100 °C.

$^1$H NMR (500 MHz, CDCl$_3$/CD$_3$OD = 19:1) δ 2.71 (t, J = 6.5 Hz, 2H, CH$_2$), 3.27 (t, J = 6.5 Hz, 2H, CH$_2$), 3.64 (s, 3H, OCH$_3$), 6.86 (d, J = 8.5 Hz, 2H, aromatic), 7.44 (d, J = 8.5 Hz, 2H, aromatic), 7.56 (d, J = 8.5 Hz, 2H, aromatic), 7.94 (d, J = 8.5 Hz, 2H, aromatic); $^{13}$C NMR (125 MHz, CDCl$_3$/CD$_3$OD = 19:1) δ 27.96 (CH$_2$), 33.21 (CH$_2$), 51.74 (CH$_3$, O-CH$_3$), 116.99 (CH, aromatic), 126.25 (CH, aromatic), 128.16 (CH, aromatic), 128.55 (CH, aromatic), 134.28 (C, aromatic), 145.52 (C-NH$_2$, aromatic), 173.63 (C, COO), 197.95 (C, CO); analysis for C$_{17}$H$_{17}$NO$_3$ calculated [M + H]$^+$ (m/z) = 284.1287 (100.0%), 285.1315 (18.4%), [M + Na]$^+$ (m/z) = 306.1106 (100.0%), 307.1134 (18.4%), [2M + Na]$^+$ (m/z) = 589.2309 (100.0%), 590.2343 (36.8%), 591.2376 (3.9%), ESI-Q-TOF HR-ESI-MS found: [M + H]$^+$ (m/z) = 284.1292 (51.6%), 285.1350 (14.9%), δ [ppm] = 0.2, [M + Na]$^+$ (m/z) = 306.1106 (66.8%), 307.1165 (17.2%), δ [ppm] = −0.2, [2M + Na]$^+$ (m/z) = 589.2288 (100.0%), 590.2331 (40.9%), 591.2340 (11.4%); δ [ppm] = −3.6.

4-(4′-fluoro-[1,1′-biphenyl]-4-yl)-4-oxobutanoic acid 6a

To a two-neck round bottomed flask was added 5a (15 mg, 0.052 mmol), TFA (1.5 mL) and H$_2$O (0.5 mL), sequentially. It was then stirred at 110 °C for 3 h. TLC (CH$_3$OH/CH$_2$Cl$_2$ = 1/19) indicated the consumption of 5a (R$_f$ = 0.94) and formation of the product 6a (R$_f$ = 0.34). After concentration under reduced pressure, the residue was chromatographed using eluents of CH$_3$OH/CH$_2$Cl$_2$ in a gradient mode of 1/49 → 1/19 to give a white solid 6a in 63% yield (9 mg, 0.033 mmol). m.p.: 133–135 °C.

$^1$H NMR (500 MHz, CDCl$_3$/CD$_3$OD = 10:1) δ 2.70 (t, J = 6.5 Hz, 2H, CH$_2$), 3.27 (t, J = 6.5 Hz, 2H, CH$_2$), 7.09 (t, J = 8.5 Hz, 2H, aromatic, H-2′), 7.52 (t, J = 8.5 Hz, 2H, aromatic), 7.75 (d, J = 8.5 Hz, 2H, aromatic); $^{13}$C NMR (125 MHz, CDCl$_3$ / CD$_3$OD = 10:1) δ 27.97 (CH$_2$), 33.42 (CH$_2$), 115.80 (d, $^2$J$_{CF}$ = 21.5 Hz, CH, aromatic), 127.02 (CH, aromatic), 128.61 (CH, aromatic), 128.84 (d, $^3$J$_{CF}$ = 8.1 Hz, CH, aromatic), 135.16 (C, aromatic), 135.87 (d, $^4$J$_{CF}$ = 2.6 Hz, C, aromatic), 144.88 (C, aromatic), 162.95 (d, $^5$J$_{CF}$ = 246.5 Hz, C, aromatic) 175.21 (C, COO), 198.35 (C,
CO); analysis for C_{16}H_{13}F_{3}O_{5}, calculated [M – H]− (m/z) = 271.0771 (100.0%), 272.0810 (17.3%), 273.0843 (1.4%), ESI-Q-TOF HR-ESI-MS found: [M – H]− = 271.0770 (100.0%), 272.0805 (17.3%), 273.0833 (2.1%), δ [ppm] = −0.15.

4-(4′-fluoro-2′-methyl-[1,1′-biphenyl]-4-yl)-4-oxobutanoic acid 6b

Reagents of 5b (45 mg, 0.15 mmol), TFA (1.5 mL) and H_{2}O (1.5 mL) were used. The procedure followed that described for preparing 6a. Reaction was allowed for 4 h and TLC (CH_{3}OH/CH_{2}Cl_{2} = 1/19) indicated the consumption of the starting material (Rf = 0.94) and formation of the product 6b (Rf = 0.42). After column chromatography, a white solid 6b was obtained in 73% yield (30 mg, 0.11 mmol). 135–138 °C.

1H NMR (500 MHz, CD_{2}OD/CDCl_{3} = 1:1) δ 2.24 (s, 3H, Ar-CH_{3}), 2.72 (t, 2H, CH), 3.08 (t, 2H, CH), 6.97 (td, 1H, J_H = 2.5 Hz, 1H, aromatic), 7.04 (dd, J = 9.5, J = 2.5 Hz, 1H, aromatic), 7.21 (dd, J = 8.0, J_H = 6.0 Hz, 2H, aromatic), 7.42 (d, J = 8.0 Hz, 2H, aromatic), 8.06 (d, J = 8.0 Hz, 2H, aromatic); 13C NMR (125 MHz, CDCl_{3}/CD_{2}OD = 1:1) δ 20.60 (Ar-CH_{3}), 29.05 (CH_{2}), 34.52 (CH_{2}), 51.84 (CH_{3}, O-CH_{3}), 113.65 (d, J_{CF} = 21.4 Hz, CH, aromatic), 117.85 (d, J_{CF} = 21.4 Hz, CH, aromatic), 129.12 (CH, aromatic), 130.70 (CH, aromatic), 132.20 (d, J_{CF} = 8.4 Hz, CH, aromatic), 136.75 (C, aromatic), 138.50 (d, J_{CF} = 2.5 Hz, C, aromatic), 139.09 (d, J_{CF} = 7.9 Hz, C, aromatic), 147.44 (C, aromatic), 163.76 (d, J_{CF} = 243.6 Hz, C, aromatic) 176.72 (C, COOH), 200.19 (C, Ar-CO); analysis for C_{17}H_{15}F_{3}O_{3}, calculated [M – H]− (m/z) = 289.0927 (100.0%), 286.0966 (18.4%), 287.1000 (1.6%), ESI-Q-TOF HR-ESI-MS found: [M – H]− = 285.0922 (100.0%), 286.0957 (18.1%), 287.0978 (2.1%), δ [ppm] = −1.7.

4-(2′,4′-difluoro-[1,1′-biphenyl]-4-yl)-4-oxobutanoic acid 6c

Reagents of 5c (96 mg, 0.32 mmol), TFA (1 mL) and H_{2}O (1 mL) were used. The procedure followed that described for preparing 6a. Reaction was allowed for 4 h and TLC (CH_{3}OH/CH_{2}Cl_{2} = 1/19) indicated the consumption of the starting material (Rf = 0.98) and formation of the product 6c (Rf = 0.32). After column chromatography, a white solid 6c was obtained in 93% yield (86 mg, 0.30 mmol). 135–138 °C.

1H NMR (500 MHz, CD_{2}OD/CDCl_{3} = 1:1) δ 2.74 (t, 2H, CH), 3.35 (t, 2H, CH), 6.97 (m, 2H, aromatic), 7.46 (q, J = 8.5 Hz, 1H, aromatic), 7.59 (m, 2H, aromatic), 8.02 (d, J = 8.5 Hz, 2H, aromatic); 13C NMR (125 MHz, CDCl_{3}/CD_{2}OD = 1:1) δ 27.23 (CH_{2}), 32.69 (CH_{2}), 51.83 (CH_{3}, O-CH_{3}), 103.69 (t, J_{CF} = 26.0 Hz, CH, C-3′), 111.14 (dd, J_{CF} = 21.3 Hz, J_{CF} = 3.5 Hz, CH, C-5′), 123.52 (dd, J_{CF} = 13.1 Hz, J_{CF} = 3.5 Hz, C, C-1′) 127.56 (CH, aromatic), 128.44 (CH, aromatic), 130.93 (dd, J_{CF} = 9.5 Hz, J_{CF} = 4.4 Hz, CH, C-6′), 134.97 (C, aromatic), 139.35 (C, aromatic), 159.45 (dd, J_{CF} = 250.0 Hz, J_{CF} = 11.9 Hz, C-F, C-2′), 162.32 (dd, J_{CF} = 248.4 Hz, J_{CF} = 11.9 Hz, C-F, C-4′), 173.33 (C, COO), 197.96 (C, CO); analysis for C_{16}H_{11}F_{3}O_{3}, calculated [M – H]− (m/z) = 289.0682 (100.0%), 290.0715 (17.3%), 291.0749 (1.4%), ESI-Q-TOF HR-ESI-MS found: [M – H]− = 289.0662 (100.0%), 290.0697 (17.1%), 291.0716 (2.0%), δ [ppm] = −6.9.
and formation of the product 6b (Rf = 0.42). After column chromatography, a white solid 6b was obtained in 73% yield (30 mg, 0.11 mmol). 135–138 °C.

Reagents of 5d (100 mg, 0.33 mmol), TFA (1 mL) and H2O (1 mL) were used. The procedure followed that described for preparing 6a. Reaction was allowed for 1.5 h and TLC (CH3OH/CH2Cl2 = 1:19) indicated the consumption of the starting material (Rf = 0.98) and formation of the product 6c (Rf = 0.32). After column chromatography, a white solid 6c was obtained in 85% yield (80 mg, 0.28 mmol). m.p.: 160–163 °C.

1H NMR (500 MHz, CDCl3/CD3OD = 1:1) δ 2.72 (t, J = 6.5 Hz, 2H, CH2), 3.32 (t, J = 6.5 Hz, 2H, CH2), 7.40 (dd, J = 8.5, 2.0 Hz, 2H, aromatic), 7.55 (dd, J = 8.5, 2.0 Hz, 2H, aromatic), 7.65 (d, J = 8.5 Hz, 2H, aromatic), 8.02 (d, J = 8.5 Hz, 2H, aromatic). 13C NMR (125 MHz, CDCl3/CD3OD = 1:1) δ 28.56 (CH2), 34.05 (CH2), 126.63 (CH, aromatic), 128.72 (CH, aromatic), 130.13 (CH, aromatic), 130.89 (CH, aromatic), 131.35 (CH, aromatic), 134.27 (C, aromatic), 135.97 (C-Cl, aromatic), 137.86 (C, aromatic), 139.98 (C, aromatic), 146.81 (C, aromatic), 174.68 (C, COO), 199.40 (C, CO); analysis for C17H15ClO3, calculated [M – H]– (m/z) = 287.0475 (100.0%), 290.0715 (17.3%), 291.0749 (2.1%) ESI-Q-TOF HR-ESI-MS found: [M – H]− = 287.0475 (51.7%), 289.0459 (22.32%), 288.0507 (16.3%), 290.0474 (1.9%) δ [ppm] = 0.07.

4-(4′-chloro-[1,1′-biphenyl]-4-yl)-4-oxobutanoic acid 6e

Reagents of 5e (30 mg, 0.095 mmol), TFA (1.5 mL) and H2O (0.5 mL) were used. The procedure followed that described for preparing 6a. Reaction was allowed for 1.5 h and TLC (CH3OH/CH2Cl2 = 1:19) indicated the consumption of the starting material (Rf = 0.98) and formation of the product 6e (Rf = 0.46). After column chromatography, a white solid 6e was obtained in 77% yield (22 mg, 0.073 mmol).

1H NMR (500 MHz, CDCl3/CD3OD = 1:1) δ 2.21 (s, 3H, Ar-CH3), 2.73 (t, J = 6.5 Hz, 2H, CH2), 3.33 (t, J = 6.5 Hz, 2H, CH2), 7.12 (d, J = 8.5 Hz, 1H, aromatic), 7.20 (dd, J = 8.5, 2.0 Hz, 1H, aromatic), 7.25 (d, J = 2.0 Hz, 1H, aromatic), 7.38 (dd, J = 8.5, 2.0 Hz, 2H, aromatic), 8.02 (d, J = 8.5 Hz, 2H, aromatic). 13C NMR (125 MHz, CDCl3/CD3OD = 1:1) δ 20.47 (Ar-CH3), 28.62 (CH2), 34.05 (CH2), 126.63 (CH, aromatic), 128.72 (CH, aromatic), 130.13 (CH, aromatic), 130.89 (CH, aromatic), 131.35 (CH, aromatic), 134.27 (C, aromatic), 135.97 (C-Cl, aromatic), 137.86 (C, aromatic), 139.98 (C, aromatic), 146.81 (C, aromatic), 174.68 (C, COO), 199.40 (C, CO); analysis for C17H15ClO3, calculated [M – H]– (m/z) = 301.0632 (100.0%), 303.0607 (32.0%), 302.0671 (18.4%), 304.0641 (5.9%), ESI-Q-TOF HR-ESI-MS found: [M – H]− = 301.0631 (100.0%), 303.0609 (33.7%), 302.0669 (19.7%), 304.0640 (7.2%), δ [ppm] = −0.06.

4-(2′,4′-dichloro-[1,1′-biphenyl]-4-yl)-4-oxobutanoic acid 6f
Reagents of 5f (105 mg, 0.31 mmol), TFA (1 mL) and H2O (1 mL) were used. The procedure followed that described for preparing 6a. Reaction was allowed for 4 h and TLC (CD3OH/CH2Cl2 = 1/19) indicated the consumption of the starting material (Rf = 0.92) and formation of the product 6f (Rf = 0.36). After column chromatography, a white solid 6f was obtained in 84% yield (84 mg, 0.26 mmol). m.p.: 135–137 °C.

1H NMR (500 MHz, CDCl3/CD3OD = 1:1) δ 2.75 (t, J = 6.5 Hz, 2H, CH2), 3.36 (t, J = 6.5 Hz, 2H, CH2), 7.29 (d, J = 8.0 Hz, 1H, aromatic), 7.33 (dd, J = 8.0, 2.0 Hz, 1H, aromatic), 7.50 (dt, J = 7.0, 2.0 Hz, 3H, aromatic), 8.02 (d, J = 8.0 Hz, 2H, aromatic); 13C NMR (125 MHz, CDCl3/CD3OD = 1:1) δ 27.22 (CH2), 32.73 (CH2), 126.72 (CH, aromatic), 127.24 (CH, aromatic), 129.02 (CH, aromatic), 129.05 (CH, aromatic), 131.31 (CH, aromatic), 132.33 (C-Cl, aromatic), 133.82 (C-Cl, aromatic), 135.15 (C, aromatic), 137.37 (C, aromatic), 142.67 (C, aromatic), 173.31 (C, COO), 197.96 (C, CO); analysis for C16H12Br2O3, calculated [M − H]− (m/z) = 410.9046 (100.0%), 408.9067 (51.4%), 412.9039 (48.6%), 411.9094 (9.7%), 325.0032 (10.2%), 326.0065 (1.8%), ESI-Q-TOF HR-ESI-MS found: [M − H]− = 410.9046 (100.0%), 408.9067 (51.4%), 412.9039 (48.6%), 411.9094 (9.7%), 325.0032 (10.2%), 326.0065 (1.8%), δ [ppm] = −3.4.

4-(3′,4′-dibromo-[1,1′-biphenyl]-4-yl)-4-oxobutanoic acid 6g

Reagents of 5g (62 mg, 0.15 mmol), TFA (1.5 mL) and H2O (0.5 mL) were used. The procedure followed that described for preparing 6a. Reaction was allowed for 2 h and TLC (CD3OH/CH2Cl2 = 1/19) indicated the consumption of the starting material (Rf = 0.98) and formation of the product 6e (Rf = 0.40). After column chromatography, a white solid 6g was obtained in 80% yield (50 mg, 0.12 mmol). 137–140 °C.

1H NMR (500 MHz, CDCl3/CD3OD = 1:1) δ 2.72 (t, J = 6.5 Hz, 2H, CH2), 3.31 (t, J = 6.5 Hz, 2H, CH2), 7.43 (d, J = 8.5 Hz, J = 2.0 Hz, 1H, aromatic), 7.64 (d, J = 8.5 Hz, 2H, aromatic), 7.68 (d, J = 8.5 Hz, 2H, aromatic), 7.86 (s, J = 2.0 Hz, 1H, aromatic), 8.03 (d, J = 8.5 Hz, 2H, aromatic); 13C NMR (125 MHz, CDCl3) δ 28.61 (CH2), 34.15 (CH2), 125.22 (C-Br, aromatic), 125.89 (C-Br, aromatic), 127.71 (CH, aromatic), 127.94 (CH, aromatic), 129.40 (CH, aromatic), 132.76 (CH, aromatic), 134.74 (CH, aromatic), 136.68 (C, aromatic), 141.27 (C, aromatic), 143.88 (C, aromatic), 175.97 (C, COO), 199.34 (C, CO); analysis for C16H12Br2O3, calculated [M − H]− (m/z) = 410.9060 (100.0%), 408.9080 (51.4%), 412.9039 (48.6%), 411.9094 (9.7%), 413.9073 (8.4%), ESI-Q-TOF HR-ESI-MS found: [M − H]− = 410.9046 (100.0%), 408.9067 (50.8%), 412.9029 (50.3%), 411.9080 (17.4%), 413.9062 (10.1%), δ [ppm] = −3.4.

4-(2′,5′-dibromo-[1,1′-biphenyl]-4-yl)-4-oxobutanoic acid 6h
Reagents of 5h (25 mg, 0.06 mmol), TFA (1.0 mL) and H2O (1.0 mL) were used. The procedure followed that described for preparing 6a. Reaction was allowed for 4 h and TLC (CH3OH/CH2Cl2 = 1/19) indicated the consumption of the starting material (Rf = 0.98) and formation of the product 6h (Rf = 0.42). After column chromatography, a white solid 6h was obtained in 67% yield (17 mg, 0.04 mmol). m.p.: 77–80 °C.

1H NMR (500 MHz, CDCl3/CD3OD = 2:1) δ 2.73 (t, J = 6.5 Hz, 2H, CH2), 3.33 (t, J = 6.5 Hz, 2H, CH2), 3.70 (s, 3H, OCH3), 7.19 (d, J = 8.0 Hz, 1H, aromatic), 7.47 (dd, J = 8.5, 2.0 Hz, 2H, aromatic) δ 7.51 (dd, J = 8.0, 2.0 Hz, 1H, aromatic), 7.82 (d, J = 2.0 Hz, 1H, aromatic), 8.02 (d, J = 8.5 Hz, 2H, aromatic); 13C NMR (125 MHz, CDCl3/CD3OD = 2:1) δ 27.46 (CH2), 32.73 (CH2), 126.72 (CH, aromatic), 127.24 (CH, aromatic), 129.12 (CH, aromatic), 130.29 (CH, aromatic), 131.53 (CH, aromatic), 134.99 (CH, aromatic), 135.36 (C, aromatic), 139.98 (C, aromatic), 144.46 (C, aromatic), 174.79 (C, COO), 198.32 (C, CO); analysis for C16H12Cl2O3, calculated [M-H]- (m/z) = 410.9060 (100.0%), 408.9080 (51.4%), 412.9030 (52.0%), 411.9087 (25.8%), 413.9068 (14.5%), δ [ppm] = −4.1.

4-(2',4'-dibromo-[1,1'-biphenyl]-4-yl)-4-oxobutanoic acid 6i

Reagents of 5i (45 mg, 0.11 mmol), TFA (1.5 mL) and H2O (0.5 mL) were used. The procedure followed that described for preparing 6a. Reaction was allowed for 4 h and TLC (CH3OH/CH2Cl2 = 1/19) indicated the consumption of the starting material (Rf = 0.98) and formation of the product 6i (Rf = 0.32). After column chromatography, a white solid 6i was obtained in 69% yield (31 mg, 0.076 mmol). m.p.: 108–110 °C.

1H NMR (500 MHz, CDCl3) δ 2.74 (t, J = 6.5 Hz, 2H, CH2), 3.34 (t, J = 6.5 Hz, 2H, CH2), 7.37 (dd, J = 8.5 Hz, J = 2.0 Hz, 1H, aromatic), 7.44 (d, J = 2.0 Hz, 1H, aromatic), 7.48 (d, J = 8.5 Hz, 2H, aromatic), 7.54 (d, J = 8.0 Hz, 1H, aromatic), 8.03 (d, J = 8.0 Hz, 2H, aromatic); 13C NMR (125 MHz, CDCl3) δ 28.62 (CH2), 34.21 (CH2), 121.52 (C-Br, aromatic), 121.95 (C-Br, aromatic), 128.58 (CH, aromatic), 130.30 (CH, aromatic), 133.06 (CH, aromatic), 134.25 (CH, aromatic), 135.37 (CH, aromatic), 136.82 (CH, aromatic), 144.07 (C, aromatic), 145.37 (C, aromatic), 175.98 (C, COO), 199.51 (C, CO); analysis for C16H12Br2O3, calculated [M-H]- (m/z) = 410.9060 (100.0%), 408.9080 (51.4%), 412.9030 (48.6%), 411.9094 (9.7%), 413.9073 (8.4%), ESI-Q-TOF HR-ESI-MS found: [M−H]− = 410.9062 (100.0%), 408.9071 (43.5%), 412.9036 (55.3%), 411.9074 (13.4%), 413.9054 (9.4%), δ [ppm] = 0.5.

4-(3',5'-dibromo-[1,1'-biphenyl]-4-yl)-4-oxobutanoic acid 6j
Reagents of 5j (85 mg, 0.20 mmol), TFA (1.0 mL) and H2O (1.5 mL) were used. The procedure followed that described for preparing 6a. Reaction was allowed for 3 h and TLC (CH3OH/CH2Cl2 = 1/19) indicated the consumption of the starting material (RF = 0.98) and formation of the product 6j (RF = 0.34). After column chromatography, a white solid 6j was obtained in 60% yield (48 mg, 0.12 mmol). m.p.: 181–183 °C.

1H NMR (500 MHz, CDCl3/CD3OD = 1:1) δ 2.74 (t, J = 6.5 Hz, 2H, CH2), 3.30 (t, J = 6.5 Hz, 2H, CH2), 7.60 (dd, J = 8.5, 2.0 Hz, 2H, aromatic), 7.65 (s, 3H, aromatic), 8.02 (d, J = 8.5 Hz, 2H, aromatic); 13C NMR (125 MHz, CDCl3/CD3OD = 1:1) δ 28.25 (CH2), 33.73 (CH2), 123.68 (C-Br, aromatic), 127.62 (CH, aromatic), 129.04 (CH, aromatic), 129.32 (CH, aromatic), 133.76 (CH, aromatic), 136.38 (C, aromatic), 143.23 (C, aromatic), 143.63 (C, aromatic), 143.13 (C, aromatic), 174.04 (C, COO), 198.44 (C, CO); analysis for C16H12Br2O3, calculated [M−H]− (m/z) = 410.9060 (100.0%), 408.9080 (51.4%), 412.9039 (48.6%), 411.9094 (9.7%), 413.9073 (8.4%), 409.9078 (8.6%), 409.9114 (4.4%), ESI-Q-TOF HR-ESI-MS found: [M−H]− = 410.9021 (100.0%), 408.9042 (50.6%), 412.9003 (46.7%), 411.9054 (16.1%), 413.9029 (12.4%), 409.9078 (8.6%), δ [ppm] = −9.5.

4-(4′-acetyl-[1,1′-biphenyl]-4-yl)-4-oxobutanoic acid 6k

Reagents of 5k (100 mg, 0.32 mmol), TFA (1.5 mL) and H2O (1.5 mL) were used. The procedure followed that described for preparing 6a. Reaction was allowed for 3 h and TLC (CH3OH/CH2Cl2 = 1/19) indicated the consumption of the starting material (RF = 0.98) and formation of the product 6j (RF = 0.34). After column chromatography, a white solid 6k was obtained in 88% yield (83 mg, 0.28 mmol). m.p.: 203–205 °C.

1H NMR (500 MHz, DMSO-d6) δ 2.60 (t, J = 6.5 Hz, 2H, Ar-COCH2), 3.28 (t, J = 6.5 Hz, 2H, CH2), 7.89 (d, J = 8.0 Hz, 4H, aromatic), 8.05 (d, J = 8.5 Hz, 2H, aromatic), 8.08 (d, J = 8.5 Hz, 2H, aromatic), 12.14 (s, 1H, -COOH); 13C NMR (125 MHz, DMSO-d6) δ 26.74 (CH3, COCH3), 27.85 (CH2), 33.17 (CH2), 127.19 (CH, aromatic), 127.23 (CH, aromatic), 128.57 (CH, aromatic), 128.28 (CH, aromatic), 135.91 (C, aromatic), 136.28 (C, aromatic), 143.13 (C, aromatic), 173.72 (C, COOH), 197.45 (C, CO), 198.03 (C, CO); analysis for C15H16O4, calculated [M−H]− (m/z) = 295.0970 (100.0%), 296.1009 (19.5%), 297.1043 (1.8%), ESI-Q-TOF HR-ESI-MS found: [M−H]− = 295.0968 (100.0%), 296.1003 (18.3%), 297.1032 (2.6%), δ [ppm] = −0.8.

4-(4′-hydroxy-[1,1′-biphenyl]-4-yl)-4-oxobutanoic acid 6l [25]
Reagents of 5l (74 mg, 0.26 mmol), TFA (3.0 mL) and H₂O (2.0 mL) were used. The procedure followed that described for preparing 6a. Reaction was allowed for 4 h and TLC (CH₃OH/CH₂Cl₂ = 1/9) indicated the consumption of the starting material (Rₛ = 0.68) and formation of the product 6l (Rₛ = 0.26). After column chromatography, a white solid 6l was obtained in 81% yield (56 mg, 0.21 mmol). m.p.: 217–220 °C.

1H NMR (500 MHz, CDC₁₃/CD₂OD = 1:1) δ 2.72 (t, J = 6.5 Hz, 2H, CH₂), 3.30 (t, J = 6.5 Hz, 2H, CH₂), 6.87 (d, J = 8.5 Hz, 2H, aromatic), 7.46 (d, J = 8.5 Hz, 2H, aromatic), 7.61 (d, J = 8.5 Hz, 2H, aromatic), 7.96 (d, J = 8.5 Hz, 2H, aromatic); 13C NMR (125 MHz, CDCl₃/CD₂OD = 1:1) δ 28.73 (CH₂), 33.94 (CH₂), 116.49 (CH, aromatic), 127.03 (CH, aromatic), 128.91 (CH, aromatic), 129.19 (CH, aromatic), 131.76 (C, aromatic), 135.14 (C, aromatic), 146.77 (C, aromatic), 158.34 (C-OH, aromatic), 174.59 (C, COO), 199.32 (C, CO); analysis for C₁₄H₁₄O₅, calculated [M–H]⁻ (m/z) = 269.0814 (100.0%), 270.0853 (17.3%), 271.0886 (1.4%), ESI-Q-TOF HR-ESI-MS found: [M–H]⁻ = 269.0810 (100.0%), 270.0843 (17.5%), 271.0868 (2.0%), δ [ppm] = −1.4.

4-(2′,4′-dihydroxy-[1,1′-biphenyl]-4-yl)-4-oxobutanoic acid 6m

Reagents of 5m (36 mg, 0.12 mmol), a solution of aqueous THF (1.2 mL, 75% vol) were used. The gold solution was cooled at 0 °C and LiOH (10 mg, 0.42 mmol, 3.5 eq) was added. After 10 min, the ice bath was removed and the reaction was allowed for 30 min and it turned dark green. A further 30 min reaction indicated the consumption of the starting material (Rₛ = 0.70) and formation of the product 6m (Rₛ = 0.38) from TLC (CH₃OH/CH₂Cl₂ = 1/9). It was treated with cationic exchange resin (H⁺) and the solution turned orange. Followed by filtration, concentration of the filtrate and column chromatography (CH₃OH/CH₂Cl₂ = 1/9) of the residue, a white solid 6m was obtained in 50% yield (18 mg, 0.06 mmol). m.p.: 210–212 °C.

1H NMR (500 MHz, CD₂OD) δ 2.70 (t, J = 6.5 Hz, 2H, CH₂), 3.32 (t, J = 6.5 Hz, 2H, CH₂), 6.39 (d, J = 8.0 Hz, 2H, aromatic), 7.14 (d, J = 8.0 Hz, 1H, aromatic), 7.66 (d, J = 8.5 Hz, 2H, aromatic), 7.97 (d, J = 8.5 Hz, 2H, aromatic); 13C NMR (125 MHz, CD₂OD) δ 29.06 (CH₂), 34.36 (CH₂), 104.11 (CH, aromatic), 108.51 (CH, aromatic), 120.29 (C, aromatic), 128.78 (CH, aromatic), 130.20 (CH, aromatic), 132.25 (CH, aromatic), 135.32 (C, aromatic), 145.94 (C, aromatic), 156.83 (C-OH, aromatic), 1589.82 (C-OH, aromatic), 176.77 (C, COOH), 200.36 (C, CO); analysis for C₁₆H₁₄O₅, calculated [M–H]⁻ (m/z) = 285.0768 (100.0%), 286.0802 (17.3%), ESI-Q-TOF HR-ESI-MS found: [M–H]⁻ = 285.0764 (100.0%), 286.0783 (19.5%), δ [ppm] = −1.4.

4-(4′-nitro-[1,1′-biphenyl]-4-yl)-4-oxobutanoic acid 6n
Reagents of 5n (100 mg, 0.32 mmol), TFA (2.5 mL) and H2O (1.0 mL) were used. The procedure followed that described for preparing 6a. Reaction was allowed for 4 h and TLC (CH3OH/CH2Cl2 = 1/19) indicated the consumption of the starting material (Rf = 0.98) and formation of the product 6n (Rf = 0.40). After column chromatography, a white solid 6n was obtained in 72% yield (70 mg, 0.23 mmol). m.p.: 157–160 °C.

**1H NMR** (500 MHz, CDCl3/CD3OD = 1:1) δ 2.73 (t, J = 6.5 Hz, 2H, CH2), 3.34 (t, J = 6.5 Hz, 2H, CH2), 7.76 (d, J = 8.5 Hz, 2H, aromatic), 7.82 (d, J = 9.0 Hz, 2H, aromatic), 8.08 (d, J = 8.5 Hz, 2H, aromatic), 8.29 (d, J = 8.5 Hz, 2H, aromatic); **13C NMR** (125 MHz, CDCl3/CD3OD = 1:1) δ 28.63 (CH2), 34.26 (CH2), 124.80 (CH, aromatic), 128.36 (CH, aromatic), 128.86 (CH, aromatic), 129.53 (CH, aromatic), 137.36 (C, aromatic), 144.04 (C, aromatic), 146.96 (C, aromatic), 148.45 (C-NO2, aromatic), 176.01 (C, COO), 199.44 (C, CO); analysis for C16H15NO3, calculated [M+H]+ = 285.0768 (100.0%), 286.0802 (17.3%), ESI-Q-TOF HR-ESI-MS found: [M+H]+ = 285.0819 (74.1%), 286.0831 (15.9%), δ [ppm] = 1.2.

4-(4′-amino-1,1′-biphenyl-4-yl)-4-oxobutanoic acid 6o

Reagents of 5o (77 mg, 0.27 mmol), TFA (1.5 mL) and H2O (1.5 mL) were used. The procedure followed that described for preparing 6a. Reaction was allowed for 1 h and TLC (CH3OH/CH2Cl2 = 1/19) indicated the consumption of the starting material (Rf = 0.80) and formation of the product 6o (Rf = 0.10). After concentration under reduced pressure, the cooled CH2Cl2 was added. The mixture was filtered through suction. Additional cooled CH2Cl2 was added to wash the solid. The solid was then concentrated under reduced pressure to afford a cream-colored solid 6o in 74% yield (53 mg, 0.20 mmol). m.p.: 150–153 °C.

**1H NMR** (500 MHz, CDCl3/CD3OD = 1:1) δ 2.73 (t, J = 6.5 Hz, 2H, CH2), 3.34 (t, J = 6.5 Hz, 2H, CH2), 7.14 (dd, J = 8.5, 2.5 Hz, 2H, aromatic), 7.61 (d, J = 8.5 Hz, 2H, aromatic), 7.66 (dd, J = 8.5, 1.5 Hz, 2H, aromatic), 8.02 (d, J = 8.0 Hz, 2H, aromatic); **13C NMR** (125 MHz, CDCl3/CD3OD = 1:1) δ 28.65 (CH2), 34.08 (CH2), 120.21 (CH, aromatic), 127.29 (CH, aromatic), 128.12 (CH, aromatic), 129.12 (CH, aromatic), 129.38 (CH, aromatic), 135.78 (C, aromatic), 145.23 (C, aromatic), 145.85 (C, aromatic), 176.06 (C, COO), 199.55 (C, CO); analysis for C14H14O4, calculated [M-H]- = 283.0704 (100.0%), 284.0753 (73.9%), 285.0796 (17.5%), 271.0868 (2.0%), ESI-Q-TOF HR-ESI-MS found: [M-H]- = 283.0708 (100.0%), 284.0757 (73.9%), 285.0798 (17.5%), 271.0868 (2.0%), δ [ppm] = −7.1.

methyl 4-(4′-((4-methylphenyl)sulfonamido)-1,1′-biphenyl-4-yl)-4-oxobutanoate 7
Compound 5o (30 mg, 0.11 mmol, 1 eq) was co-distilled using toluene and CH$_2$Cl$_2$ three times followed by drying under high vacuo for 30 min. Dissolving by CH$_2$Cl$_2$ (0.5 mL) and adding pyridine (17 mg, 0.22 mmol, 2 eq), the mixture was cooled to 0 °C. p-TsCl (42 mg, 0.22 mmol, 2 eq) was added and the stirring was allowed for 10 min. Followed by removing the ice bath, the mixture turned from orange to pink during the next 30 min at rt. TLC (EtOAc/CH$_2$Cl$_2$ = 1/39) indicated the consumption of 5o ($R_f$ = 0.4) and formation of the product 7 ($R_f$ = 0.32). After a further 17 h reaction, 1N HCl$_{aq}$ (4.5 mL) was added followed by partitioning using CH$_2$Cl$_2$ (15 mL). Following washing with sat. NaCl$_{aq}$ (3 mL) and collecting the organic layer, the aqueous layer was back extracted using CH$_2$Cl$_2$ (15 mL) twice. Combining the organic layers and drying over MgSO$_4$, the mixture was filtered through gravitational filtration. The filtrate was concentrated under reduced pressure for subsequent flash chromatography using eluents (EtOAc/CH$_2$Cl$_2$ = 1:49) to afford white powder (88 mg). The analytic sample (58 mg) was crystallized from toluene to give white powder 7 in 48% yield (29 mg, 0.07 mmol). m.p.: 174–178 °C.

$^1$H NMR (500 MHz, CDCl$_3$) $\delta$ 2.46 (s, 3H, CH$_3$, H$_{tosyl}$), 2.78 (t, $J$ = 6.5 Hz, 2H, CH$_2$), 3.34 (t, $J$ = 6.5 Hz, 2H, CH$_2$), 5.70 (s, 3H, -OCH$_3$), 6.76 (bs, 1H, -NH), 7.14 (d, $J$ = 8.5 Hz, 2H, aromatic), 7.23 (d, $J$ = 8.5 Hz, 2H, aromatic), 7.48 (d, $J$ = 8.0 Hz, 2H, aromatic, H$_{tosyl}$), 7.58 (d, $J$ = 8.5 Hz, 2H, aromatic), 7.68 (d, $J$ = 8.0 Hz, 2H, aromatic, H$_{tosyl}$), 8.00 (d, $J$ = 8.5 Hz, 2H, aromatic), $^{13}$C NMR (125 MHz, CDCl$_3$) $\delta$ 121.74 (CH, aromatic), 128.36 (CH, aromatic), 128.68 (CH, aromatic), 129.74 (CH, aromatic), 135.27 (C, aromatic), 136.21 (C, aromatic), 136.61 (C, aromatic), 136.75 (C, aromatic), 144.04 (C, aromatic), 144.69 (C, aromatic), 173.42 (C, COO), 197.54 (C, CO); analysis for C$_{28}$H$_{20}$NO$_5$S, calculated [M + Na]$^+$ ($m/z$) = 460.1189 (100.0%), 461.1223 (26.0%), ESI-Q-TOF HR-ESI-MS found: [M + Na]$^+$ = 460.1187 (65.4%), 461.1216 (18.2%), $\delta$ [ppm] = −0.4.

4-(4'-(4-methylphenyl)sulfonylamido)-1,1'-biphenyl)-4-yl)-4-oxobutanoic acid 8

Reagents of 7 (17 mg, 0.04 mmol) and a solution of aqueous THF (0.6 mL, 75% v/v) were used. The gold solution was cooled at 0 °C and LiOH (2.9 mg, 0.12 mmol, 3.0 eq) was added. After 10 min, the ice bath was removed and the reaction was allowed for 1 h. TLC (CH$_3$OH/CH$_2$Cl$_2$ = 1:19) indicated the consumption of the starting material 7 ($R_f$ = 0.84) and formation of the product 8 ($R_f$ = 0.30). It was treated with cationic exchange resin (strong H$^+$). Followed by filtration and concentration of the filtrate, a white solid 8 was obtained in 75% yield (12.8 mg, 0.03 mmol). m.p.: 165–167 °C.

$^1$H NMR (500 MHz, CD$_3$OD/CDCl$_3$ = 1:1) $\delta$ 2.33 (s, 3H, CH$_3$, H$_{tosyl}$), 2.71 (t, $J$ = 6.5 Hz, 2H, CH$_2$), 3.30 (t, $J$ = 6.5 Hz, 2H, CH$_2$), 7.17 (d, $J$ = 8.5 Hz, 2H, aromatic), 7.22 (d, $J$ = 8.0 Hz, 2H, aromatic, H$_{tosyl}$), 7.47 (d, $J$ = 8.5 Hz, 2H, aromatic), 7.59 (d, $J$ = 8.5 Hz, 2H, aromatic).
Molecules 2022, 27, 2850  

To a flask (250 mL) was added the bromo compound 2 (500 mg, 1.8 mmol, 1 eq) into THF (8 mL). The borono compound, 4-boropinacol phenethylmethanol (464 mg, 2.0 mmol, 1.1 eq), Pd(PPh3)4 (104 mg, 0.09 mmol, 0.05 eq) and aqueous K2CO3 (4.5 g, 32.4 mmol, 18 eq) in H2O (1 mL) were added, sequentially. The reaction was allowed at a gentle-reflux condition for 4 h (one drop per second). TLC (acetone/n-hexane = 3:7) indicated the consumption of the starting material (Rf = 0.56) and formation of the product 12 (Rf = 0.20). The mixture was partitioned between EtOAc (30 mL) and aqueous saline (satd., 15 mL × 3). The organic layer was collected, dried over Na2SO4, filtered through a celite pad. The filtrate was concentrated and chromatographed using eluents acetone/n-hexane in a gradient mode from 3:7 to 4:6 to afford a white solid which formed a transparent yellow solid under a high vacuum. The yield was 38% (205 mg). 1H NMR (500 MHz, CDCl3) δ 2.73 (t, J = 6.7 Hz, 2H, HAliphatic), 3.21 (t, J = 6.7 Hz, 2H, HAliphatic), 3.65 (s, 3H, HOCH3), 4.70 (s, 2H, CH2), 7.47 (d, J = 8.5 Hz, 2H, HAr), 7.62 (d, J = 8.0 Hz, 2H, HAr), 7.68 (d, J = 8.5 Hz, 2H, HAr), 8.06 (d, J = 8.5 Hz, 2H, HAr). 13C NMR (125 MHz, CDCl3) δ 28.00 (aliphatic, CH2), 33.40 (aliphatic, CH2), 51.85 (OCH3, CH3), 64.84 (OH-CH2, CH2), 127.14 (Ar, CH), 127.38 (Ar, CH), 127.49 (Ar, CH), 128.45 (Ar, CH), 128.54 (Ar, CH), 128.63 (Ar, CH), 128.72, 130.91 (Ar, CH), 131.97 (Ar, CH), 132.02 (Ar, CH), 132.10 (Ar, CH), 135.21 (Ar, C), 139.06 (Ar, C), 141.09 (Ar, C), 145.51 (Ar, C), 173.42 (C, COO).
1H NMR (500 MHz, CDCl3/CD3OD = 1:1) δ 2.39 (t, J = 6.5 Hz, 2H, CH2), 2.96 (t, J = 6.5 Hz, 2H, CH2), 4.32 (s, 2H, CH2OH), 7.09 (d, J = 8.0 Hz, 2H, aromatic), 7.26 (d, J = 8.0 Hz, 2H, aromatic); 13C NMR (125 MHz, CDCl3/CD3OD = 1:1) δ 28.74 (CH2), 34.15 (CH2), 64.52 (CH2), 127.72 (CH, aromatic), 127.78 (CH, aromatic), 128.09 (CH, aromatic), 129.27 (CH, aromatic), 136.05 (C, aromatic), 139.45 (C, aromatic), 142.32 (C, aromatic), 146.54 (C, aromatic), 176.00 (C, COO), 199.65 (C, CO); analysis for C17H16O4, calculated [M + H]+ (m/z) = 285.1121 (100.0%), 286.1155 (18.4%), [M + Na]+ (m/z) = 307.0941 (100.0%), 308.0974 (18.4%), δ [ppm] = 1.1, [M + Na]+ (m/z) = 307.0943 (12.5%), 308.0973 (2.1%), δ [ppm] = 0.7.

4.3. Bioassay

4.3.1. IL-1β Assay

Inhibition against the IL-1 beta expression level followed the same procedure that had been published previously by Hua GF and coworkers [50,51]. In brief, the mouse macrophage cell line J774A.1 purchased from the American Type Culture Collection (Rockville, MD) were primed for 5 h with 1 µg/mL lipopolysaccharide followed by treatment with the compounds in 50 µM and the standard MCC950 in 1 µM for 30 min. The mixture was then treated with 5 mM ATP for 0.5 h. The supernatants were then collected for assaying the IL-β using Elisa according to the brochure’s instruction—Invitrogen cat. No. 887013. The absorbance at λmax of 450 nm were measured. The data were corrected by subtracting the absorbance at λmax of 570 nm. Data were obtained in triplicate that had been corrected for the control group.

4.3.2. COX-1 and COX-2 Inhibition Assay

Assay kit (No. 560131) from Cayman was used for screening bioactivity. The flowcharts have been appended as Supplementary Material. In brief, the volume of compound solution and the reagents used for this assay were increased from 10 to 20 µL in order that a multipipetting was performable. Ten microliters of Heme was diluted using 520 µL buffer solution. It was distributed to 7 tubes by 70 µL and the last tube by 40 µL. SnCl2 solution was prepared by dissolving 45 mg in HCl (0.9 mL) and distributing 120 µL to 8 tubes. The arachidonic acid solution was prepared by mixing a portion of 5 µL with 5 µL of KOH (aq) by vortex followed by dissolving with 1 mL H2O. It was distributed to 8 tubes in 125 µL amounts for each. A volume of 45 µL of COX enzyme dissolved in 415 µL buffer was ready for the subsequent procedure. In stage 2, all the reagents and compounds were added at volumes of 20 µL or 30 µL per multi pipetting, except the addition of COX enzymes. The last Elisa assay was performed by using the 2000-fold dilution and the addition stage was per multipipetting. The rest of development was the same as that described.

4.4. In Silico Modeling and Simulation

4.4.1. Treatment before Docking Procedure

The sequence of enzymes COX-1 and COX-2 were retrieved from the two templates registered in PDB bank bearing the codes of 1EQG and 1CX2, respectively. They were both derived from the co-crystallization with the substrates of ibuprofen and bromocolecoxib, respectively. Ibuprofen is a COX-1 and COX-2 inhibitor with no selectivity. SC-558 (bromocolecoxib), like celecoxib, is a selective COX-2 inhibitor and is used as a template protein for present study. Before the molecular docking analysis, Discovery Studio’s (DS) Prepare Protein and Prepare Ligands were used to modify the charge distribution. The receptor part, i.e., the two COX enzymes, were both administered in the CHARMM force field throughout the whole docking process although the protein conformation seems not to be changed significantly. The flexible receptor atom property is enabled by creating a sphere radiating from a center defined by PDB crystal data in a radius of 4 Å as referred to the published work (Figure 11) [42,43]. The two sites contain mostly involved residues including Arg120 and Tyr355 for COX-1 and His90, Gln192, Arg513, Ser353, Tyr355 and
Phe518 for COX-2. The sphere with a radius of 4 Å created in 1EQG covers additional residues, such as Val116, Arg120, Tyr348, Val349, Leu352, Ser353, Tyr355, Leu359, Phe381, Leu384, Tyr385, Trp387, Phe518, Met522, Ile523, Gly526, Ala527, Ser530 and Leu531; a volume for COX-2 (1CX2) encompasses residues of His90, Val116, Arg120, Gln192, Val349, Leu352, Ser353, Tyr355, Leu359, Phe381, Leu384, Tyr385, Trp387, Arg513, Ala516, Ile517, Phe518, Val523, Gly526, Ala527, Ser530 and Leu531.

Figure 11. The plots of three-dimensional COX-1 (1EQG) and COX-2 (1CX2) are shown in the left and right panels. Each of them contains a grey sphere redefined as an active site with a 4 Å radius. The residues marked with yellow were suggested to be involved in the binding.

4.4.2. Algorithms and Scoring Functions

In Situ Ligand Minimization Algorithm

Available options for establishing the algorithm encompasses adopted basis Newton–Raphson (NR), steepest descent and conjugate gradient. NR is applied to a subspace of the coordinate vector spanned by the displacement coordinates of the last positions. In each step of this iterative procedure, the coordinates are adjusted in the negative direction of the gradient. Steepest descent does not generally converge, but will rapidly improve a very poor conformation. Conjugate gradient is an iterative method which makes use of the previous history of minimization steps as well as the current gradient to determine the next step. It has better convergence characteristics but is subject to numerical overflows when starting with very poor conformations. Energy minimization through these procedures will be scored using the smart minimizer function.

Conformation Method

Algorithm for generating conformations was enabled by adopting the option of FAST mode. This could provide rational numbers of low-energy conformation in a reasonable time.

Entropy Minimization

Similar to above in situ ligand minimization algorithm, the entropy component for the ligand conformation was also minimized using the tree approaches.
Implicit Solvent Model

Issues involved in this calculation regard the Coulomb repulsion and dielectric attraction. The option of Poisson–Boltzmann with non-polar surface area (PBSA) was adopted. PBSA is the most rigorous yet slowest solvent approximation method based on continuum electrostatics. This may not be available if in situ ligand minimization is running.

Implicit Solvent Dielectric Constant

The model used for dielectric constant for bulk solvent used is PBSA.

Salt Concentration

The solvation condition was generated through common settings, such as using NaCl as the salt and concentration was set to 0.145 M.

4.4.3. Simulation Procedure

The docking simulation was performed using DS 2021 software integrated with the DS flexible docking protocol mode. The flexible algorithm allows the bound residue to fit in a reasonable manner. The pretreatment was the same as that described for the former docking simulation in Section 4.4.1. The solvation condition was generated through common settings, such as using NaCl as the salt and concentration in 0.145 M. The subsequent standard dynamics cascade protocol simulates the molecular dynamics through energy minimization and a number of stages, e.g., heating, equilibration and production. The procedures of steepest descent and conjugate gradient were used to converge as described above. The isothermal and isobaric ensemble conditions were set to perform the dynamics calculation. The candidate conformation was further analyzed in terms of trajectory based on the deviation from the initial atomic state which was described by two functions of root-mean-square deviation, RMSD, and root-mean-square fluctuation, RMSF.

The parameters were set to allow for maximum conformation numbers of ligand of 255, docking numbers of hotspot of 100 and energy threshold of 20. The probable conformations were submitted to DS Analyze Ligand Poses and Docking Pose in order to minimize binding free energy. A further validation using DS Calculate Binding Energies to compare the results from the two calculations can identify the most optimized conformation. All the free energy calculations will be enrolled in the following expression:

$$
\Delta G_{binding} = \Delta G_{complex} - \Delta G_{ligand} - \Delta G_{enzyme}.
$$

The free energy calculation generates two classes of data expression: the preliminary binding energy of the system in the CHARMm condition and, additionally, the free energy resulting from the presence of solvent effect.

4.4.4. Validation of Computational Program

The most optimal docking poses by the two benchmarking inhibitors, i.e., celecoxib and ibuprofen, were each superimposed with bromocelecoxib (SC58) and ibuprofen itself (Figures 12 and 13). The latter two conformations were derived from the original co-crystallized complexes 1EQG and 1CX2, respectively. The two orientations of ibuprofen from the original complex and from simulation showed an RMSD value of 5.649 Å, a value relatively larger than the reported 0.433 Å [44]. The subtle shift in placement may be related to broader defining of the sphere covering the active site. When comparing bromocelecoxib (SC558) with celecoxib, an RMSD value of 6.615 Å is almost comparable to that of the ibuprofen group.
Figure 12. Overlaying of bromocelecoxib (SC558) pose retrieving from PDB data base (1CX2) with celecoxib from the docking result. Original pose from PDB specified in blood red and the pose from docking result marked in purple. RMSD = 6.615 Å.

Figure 13. Overlaying of the two ibuprofen poses originating from that retrieving from PDB data base (1EQG) and from that of the docking result. Original pose from PDB specified in blood red and the pose from docking result marked in purple. RMSD = 5.649 Å.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules27092850/s1, including docking results of 6l and 6o as well as the spectra data and bioassay flowchart.

Author Contributions: Conceptualization, C.-S.Y.; methodology, Y.-B.L., K.-F.H., H.-P.C. and T.-Y.Y.; software, S.-N.L., L.-H.S. and S.-S.F.; Writing, C.-S.Y.; funding acquisition, R.-J.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Ministry of Science and Technology of Taiwan MOST-109-2113-M-007-016.

Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: Huai-En Yu was acknowledged for his assistance in experiment.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Not applicable.

References

1. Moore, N.; Carleton, B.; Blin, P.; Bosco-Levy, P.; Droz, C. Does Ibuprofen Worsen COVID-19? Drug Saf. 2020, 43, 611–614. [CrossRef] [PubMed]

2. Ong, S.W.X.; Tan, W.Y.T.; Chan, Y.H.; Fong, S.W.; Renia, L.; Ng, L.F.P.; Leo, Y.S.; Yee, D.C.; Young, B.E. Safety and potential efficacy of cyclooxygenase-2 inhibitors in coronavirus disease 2019. Clin. Transl. Immunol. 2020, 9, e1159. [CrossRef] [PubMed]

3. Prasher, P.; Sharma, M.; Gunupuru, R. Targeting cyclooxygenase enzyme for the adjuvant COVID-19 therapy. Drug Dev. Res. 2021, 82, 469–473. [CrossRef] [PubMed]

4. Jackson, L.M.; Wu, K.C.; Mahida, Y.R.; Jenkins, D.; Hawkey, C.J. Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa. Gut 2000, 47, 762–770. [CrossRef]

5. Berbecka, M.; Wu, K.C.; Mahida, Y.R.; Jenkins, D.; Hawkey, C.J. Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa. Gut 2000, 47, 762–770. [CrossRef]

6. Vecchio, A.J.; Simmons, D.M.; Malkowski, M.G. Structural Basis of Fatty Acid Substrate Binding to Cyclooxygenase-2. Proc. Natl. Acad. Sci. USA 2002, 99, 13371–13373. [CrossRef] [PubMed]

7. Warner, T.D.; Mitchell, J.A. Cyclooxygenase-3 (COX-3): Filling in the gaps toward a COX continuum? Proc. Natl. Acad. Sci. USA 2002, 99, 13371–13373. [CrossRef] [PubMed]

8. Simmons, D.L.; Botting, R.M.; Hla, T. Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 2004, 56, 387–437. [CrossRef] [PubMed]

9. Smith, W.L.; Urade, Y.; Jakobsson, P.J. Enzymes of the Cyclooxygenase Pathways of Prostanoid Biosynthesis. Chem. Rev. 2011, 111, 5821–5865. [CrossRef]

10. Vecchio, A.J.; Simmons, D.M.; Malkowski, M.G. Structural Basis of Fatty Acid Substrate Binding to Cyclooxygenase-2. J. Biol. Chem. 2010, 285, 22152–22163. [CrossRef]

11. Daniels, M.J.D.; Rivers-Auty, J.; Schilling, T.; Spencer, N.G.; Wattrenez, W.; Fasolino, V.; Booth, S.J.; White, C.S.; Baldwin, A.G.; Freeman, S.; et al. Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer’s disease in rodent models. Nat. Commun. 2016, 7, 12504. [CrossRef] [PubMed]

12. Weggen, S.; Eriksen, J.L.; Das, P.; Sagi, S.A.; Wang, R.; Pietrzik, C.U.; Findlay, K.A.; Smith, T.E.; Murphy, M.P.; Butler, T.; et al. A subset of NSAIDs lower amyloidogenic A beta 42 independently of cyclooxygenase activity. Nature 2001, 414, 212–216. [CrossRef] [PubMed]

13. Zhang, X.N.; Xu, A.; Lv, J.H.; Zhang, Q.Q.; Ran, Y.Y.; Wei, C.; Wu, J.D. Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases. Eur. J. Med. Chem. 2020, 185, 118822. [CrossRef] [PubMed]

14. Lamkanfi, M.; Mueller, J.L.; Vitari, A.C.; Misaghi, S.; Fedorova, A.; Deshayes, K.; Lee, W.P.; Hoffman, H.M.; Dixit, V.M. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J. Cell Biol. 2009, 187, 61–70. [CrossRef]

15. Huang, H.L.; Yeh, C.N.; Lee, W.Y.; Huang, Y.C.; Chang, K.W.; Lin, K.J.; Tien, S.F.; Su, W.C.; Yang, C.H.; Chen, J.T.; et al. I-123 Iodoctyl fenbufen amide as a SPECT tracer for imaging tumors that over-express COX enzymes. Biomaterials 2013, 34, 3355–3365. [CrossRef] [PubMed]

16. Huang, Y.C.; Chang, Y.C.; Yeh, C.N.; Yu, C.S. Synthesis and Biological Evaluation of an (18)Fluorine-Labeled COX Inhibitor- F-18 Fluoroocetyl Fenbufen Amide-For Imaging of Brain Tumors. Molecules 2016, 21, 387. [CrossRef]

17. Huang, Y.C.; Farn, S.S.; Chou, Y.C.; Yeh, C.N.; Chang, C.W.; Chung, Y.H.; Chen, T.W.; Huang, W.S.; Yu, C.S. Synthesis of para-F-18 Fluorofenbufen Octylamide for PET Imaging of Brain Tumors. J. Clin. Chem. Soc. 2018, 65, 780–792. [CrossRef]

18. Chang, C.W.; Yeh, C.N.; Chung, Y.H.; Chen, Y.R.; Tien, S.W.; Chen, T.W.; Farn, S.S.; Huang, Y.C.; Yu, C.S. Synthesis and evaluation of ortho- F-18 fluorocecloxib for COX-2 cholangiocarcinoma imaging. Drug Des. Dev. Ther. 2018, 12, 1467–1478. [CrossRef]

19. Yeh, C.N.; Chang, C.W.; Chung, Y.H.; Tien, S.W.; Chen, Y.R.; Chen, T.W.; Huang, Y.C.; Wang, H.E.; Chou, Y.C.; Chen, M.H.; et al. Synthesis and characterization of boron fenbufen and its F-18 labeled homolog for boron neutron capture therapy of COX-2 overexpressed cholangiocarcinoma. Eur. J. Pharm. Sci. 2017, 107, 217–229. [CrossRef] [PubMed]

20. Purchase, C.F.; Roth, B.D.; White, A.D.; Schielke, G.P.; Walker, L.C. Preparation of Biphenylbutyric Acids and Their Derivatives as Inhibitors of Matrix Metalloproteinases. Patent WO9809940A1, 12 March 1998.

21. Teufel, H.; Engel, W.; Seeger, E.; Nickl, J. 4-(4-Biphenyl)-4-oxobutyric Acid Derivatives. Patent DE2112716A, 5 October 1972.

22. Seeger, E.; Nickl, J.; Engel, W.; Teufel, H. 4-(4-Biphenyl)-4-hydroxybutyric Acid Derivatives. Patent DE2112715A, 5 October 1972.
23. Shichita, T.; Yoshikawa, K.; Takashima, K.; Himizu, J.; Takada, T.; Tsuzurahara, K. 3-Benzoylpropionic Acids and Esters. Patent JP4904263A1, 1974.

24. Krausz, F.; Brunaud, M.D.P. Glycerol Esters of 4-Phenybutyric Acid and Its Derivatives for Use in Pharmaceuticals. Patent DE243437A1, 13 February 1975.

25. Ranganathan, T.; Ramesh, C.; Kumar, A. Effect of connectivity and terminal functionality on mesophase behaviour of thermotropic liquid crystals containing biphenyl units. *Liq. Cryst.* **2005**, *32*, 499–512. [CrossRef]

26. Kuchar, M.; Vosatka, V.; Poppova, M.; Knezova, E.; Panajotovova, V.; Tomkova, H.; Taimr, J. Some analogs of 4-(2',4'-difluorobiphenyl-4-yl)-2-methyl-4-oxobutanoic acid—synthesis and antiinflammatory activity. *Collect. Czechoslov. Chem. Commun.* **1995**, *60*, 1026–1033. [CrossRef]

27. Nickl, J.; Teufel, H.; Seeger, E.; Engel, W. 4-(4-Biphenyl)butyric Acid Derivatives. Patent DE2112840A, 5 October 1972.

28. Chiccarelli, F.S.; Eisner, H.J.; Van Lear, G.E. Disposition and metabolism of fenbufen in several laboratory animals. *Arzneimittel-Forschung* **1980**, *30*, 707–715. [PubMed]

29. Child, R.G.; Osterberg, A.C.; Slobod, A.E.; Tomcufcik, A.S. Fenbufen, a New Anti-Inflammatory Analgesic—Synthesis and Structure-Activity-Relationships of Analogs. *J. Pharm. Sci.* **1977**, *66*, 446–476. [CrossRef] [PubMed]

30. Lennox, A.J.J.; Lloyd-Jones, G.C. Selection of boron reagents for Suzuki-Miyaura coupling. *Chem. Soc. Rev.* **2014**, *43*, 412–443. [CrossRef]

31. Miyaura, N. Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds. *Chem. Rev.* **1995**, *95*, 2457–2483. [CrossRef]

32. Burda, E.; Bauer, W.; Hummel, W.; Groger, H. Enantio- and Diastereoselective Chemoenzymatic Synthesis of C2-Symmetric Biaryl-Containing Diols. *Chemcatchem* **2010**, *2*, 67–72. [CrossRef]

33. Miyaura, N.J.M.C.C.C.R. Metal-catalyzed cross-coupling reactions of organoboron compounds with organic halides. *ChemInform* **2004**, *36*, 41–123.

34. Sarmah, G.; Mondal, M.; Bora, U. Alcoholic solvent-assisted ligand-free room temperature Suzuki-Miyaura cross-coupling reaction. *Appl. Organomet. Chem.* **2013**, *29*, 495–498. [CrossRef]

35. Sharif, M.; Zeeshan, M.; Reimann, S.; Villinger, A.; Langer, P. One-pot synthesis of fluorinated terphenyls by site-selective Suzuki-Miyaura reactions of 1,4-dibromo-2-fluorobenzene. *Tetrahedron Lett.* **2010**, *51*, 2810–2812. [CrossRef]

36. Sovocool, G.W.; Wilson, N.K. Differentiation of Brominated Biphenyls by C-13 Nuclear Magnetic-Resonance and Gas-Chromatography Mass-Spectrometry. *J. Org. Chem.* **1982**, *47*, 4032–4037. [CrossRef]

37. Protection for the Carboxyl Group. In *Greene’s Protective Groups in Organic Synthesis*; John Wiley & Sons: New York, NY, USA, 2014; pp. 686–836.

38. Mangan, M.S.J.; Olhava, E.J.; Roush, W.R.; Seidel, H.M.; Glick, G.D.; Latz, E. Targeting the NLRP3 inflammasome in inflammatory diseases. *Nat. Rev. Drug Discov.* **2018**, *17*, 588–606. [CrossRef] [PubMed]

39. Cocco, M.; Miglio, G.; Garella, D.; Marini, E.; Costale, A.; Regazzoni, L.; Vistoli, G.; Orioli, M.; Massulaha-Ahmed, R.; et al. Design, Synthesis, and Evaluation of Acrylamide Derivatives as Direct NLRP3 Inflammasome Inhibitors. *ChemMedChem* **2016**, *11*, 1790–1803. [CrossRef] [PubMed]

40. Fulp, J.; He, L.; Toldo, S.; Jiang, Y.Q.; Boice, A.; Guo, C.Q.; Li, X.; Rolfe, A.; Sun, D.; Abbate, A.; et al. Structural Insights of Benzenesulfonamide Analogues as NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization. *J. Med. Chem.* **2018**, *61*, 5412–5423. [CrossRef] [PubMed]

41. Kameo, K.; Ogawa, K.; Takeda, K.; Nakaiake, S.; Sota, K. Studies on antirheumatic agents—3-benzoylpropionic acidderivatives. *Chem. Pharm. Bull.* **1988**, *36*, 2050–2060. [CrossRef] [PubMed]

42. Selinsky, B.S.; Gupta, K.; Sharkey, C.T.; Loll, P.J. Structural analysis of NSAID binding by prostaglandin H-2 synthase: Time-dependent and time-independent inhibitors elicit identical enzyme conformations. *Biochemistry* **2001**, *40*, 5172–5180. [CrossRef] [PubMed]

43. Kurumbail, R.G.; Stevens, A.M.; Gierse, J.K.; McDonald, J.J.; Stegeman, R.A.; Pak, J.Y.; Gildehaus, D.; Miyashiro, J.M.; Penning, T.D.; Seibert, K.; et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. *Nature* **1996**, *384*, 644–648. [CrossRef]

44. Dhankar, R.; Rahaatgaonkar, A.M.; Shukla, R.; Chorghade, M.; Tiwari, A. Computer simulation of the in vitro and in vivo anti-inflammatory activities of dihydropyrimidines acid derivatives through the inhibition of cyclooxygenase-2. *Med. Chem. Res.* **2013**, *22*, 2493–2504. [CrossRef]

45. Rashad, A.Y.; Kassab, S.E.; Daabees, H.G.; Moneim, A.E.A.; Rostom, S.A.F. Fexofenastat-based amides and some derived heterocycles targeting xanthine oxidase and COX inhibition. Synthesis, in vitro and in vivo biological evaluation, molecular modeling and in silico ADMET studies. *Bioorg. Chem.* **2021**, *113*, 104948. [CrossRef]

46. Lutz, R.E.; Scott, G.W. CIS and trans beta-aroylacrylic acids and some derivatives. *J. Org. Chem.* **1948**, *13*, 284–296. [CrossRef]

47. de Filippis, A.; Morin, C.; Thimon, C. Synthesis of some para-functionalized phenylboronic acid derivatives. *Synth. Commun.* **2002**, *32*, 2669–2676. [CrossRef]

48. Quin, C.; Robertson, L.; McQuaker, S.J.; Price, N.C.; Brand, M.D.; Hartley, R.C. Caged mitochondrial uncouplers that are released in response to hydrogen peroxide. *Tetrahedron* **2010**, *66*, 2384–2389. [CrossRef] [PubMed]

49. Curran, W.V.; Ross, A. 6-Phenyl-4,5-dihydro-3(2H)-pyridazinones. A series of hypotensive agents. *J. Med. Chem.* **1974**, *17*, 273–281. [CrossRef]
50. Chiu, H.W.; Li, L.H.; Hsieh, C.Y.; Rao, Y.K.; Chen, F.H.; Chen, A.; Ka, S.M.; Hua, K.F. Glucosamine inhibits IL-1 beta expression by preserving mitochondrial integrity and disrupting assembly of the NLRP3 inflammasome. Sci. Rep. 2019, 9, 5603. [CrossRef] [PubMed]

51. Wu, C.H.; Gan, C.H.; Li, L.H.; Chang, J.C.; Chen, S.T.; Menon, M.P.; Cheng, S.M.; Yang, S.P.; Ho, C.L.; Chernikov, O.V.; et al. A Synthetic Small Molecule F240B Decreases NLRP3 Inflammasome Activation by Autophagy Induction. Front. Immunol. 2020, 11, 607564. [CrossRef] [PubMed]